WO2010054221A2 - Treatment of chronic inflammatory respiratory disorders - Google Patents
Treatment of chronic inflammatory respiratory disorders Download PDFInfo
- Publication number
- WO2010054221A2 WO2010054221A2 PCT/US2009/063584 US2009063584W WO2010054221A2 WO 2010054221 A2 WO2010054221 A2 WO 2010054221A2 US 2009063584 W US2009063584 W US 2009063584W WO 2010054221 A2 WO2010054221 A2 WO 2010054221A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vegf
- npl
- inhibitor
- vegfr2
- crswnp
- Prior art date
Links
- 230000001684 chronic effect Effects 0.000 title claims abstract description 23
- 230000002757 inflammatory effect Effects 0.000 title claims abstract description 23
- 208000023504 respiratory system disease Diseases 0.000 title claims abstract description 23
- 238000011282 treatment Methods 0.000 title description 20
- 238000000034 method Methods 0.000 claims abstract description 75
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims abstract description 62
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims abstract description 62
- 230000014509 gene expression Effects 0.000 claims abstract description 61
- 230000000694 effects Effects 0.000 claims abstract description 49
- 239000003112 inhibitor Substances 0.000 claims abstract description 44
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 43
- 210000004027 cell Anatomy 0.000 claims description 94
- 108090000772 Neuropilin-1 Proteins 0.000 claims description 82
- 102000004207 Neuropilin-1 Human genes 0.000 claims description 81
- 108020004459 Small interfering RNA Proteins 0.000 claims description 60
- 210000002919 epithelial cell Anatomy 0.000 claims description 60
- 239000004055 small Interfering RNA Substances 0.000 claims description 53
- 230000000903 blocking effect Effects 0.000 claims description 43
- 230000002401 inhibitory effect Effects 0.000 claims description 35
- 208000006673 asthma Diseases 0.000 claims description 27
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims description 27
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 26
- 238000000338 in vitro Methods 0.000 claims description 25
- 230000012010 growth Effects 0.000 claims description 24
- 108091008605 VEGF receptors Proteins 0.000 claims description 22
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 22
- 208000015768 polyposis Diseases 0.000 claims description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 17
- 230000006907 apoptotic process Effects 0.000 claims description 16
- 230000003305 autocrine Effects 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 230000035755 proliferation Effects 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 7
- 150000003384 small molecules Chemical class 0.000 claims description 7
- 230000004083 survival effect Effects 0.000 claims description 7
- 238000001990 intravenous administration Methods 0.000 claims description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
- 108091008103 RNA aptamers Proteins 0.000 claims description 4
- JMGXJHWTVBGOKG-UHFFFAOYSA-N [4-chloro-3-[5-methyl-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-benzotriazin-7-yl]phenyl] benzoate Chemical compound N1=C2C(C)=CC(C=3C(=CC=C(OC(=O)C=4C=CC=CC=4)C=3)Cl)=CC2=NN=C1NC(C=C1)=CC=C1OCCN1CCCC1 JMGXJHWTVBGOKG-UHFFFAOYSA-N 0.000 claims description 4
- 229960000397 bevacizumab Drugs 0.000 claims description 4
- 230000036961 partial effect Effects 0.000 claims description 4
- 230000009885 systemic effect Effects 0.000 claims description 4
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 4
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 4
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 4
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 claims description 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 3
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims description 3
- 206010040749 Sinus polyp Diseases 0.000 claims description 3
- PRYZSLKPMFOUNL-MHIBGBBJSA-N bevasiranib Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2CO)N2C3=NC=NC(N)=C3N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C(N=C(N)C=C2)=O)O)N2C(NC(=O)C=C2)=O)O)N2C(N=C(N)C=C2)=O)O)N2C3=NC=NC(N)=C3N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C(N=C(N)C=C2)=O)O)N2C3=NC=NC(N)=C3N=C2)O)N2C3=NC=NC(N)=C3N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C(N=C(N)C=C2)=O)O)N2C3=NC=NC(N)=C3N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C3=NC=NC(N)=C3N=C2)O)N2C(N=C(N)C=C2)=O)O)[C@@H](O)C1 PRYZSLKPMFOUNL-MHIBGBBJSA-N 0.000 claims description 3
- 229950006615 bevasiranib Drugs 0.000 claims description 3
- 229960000639 pazopanib Drugs 0.000 claims description 3
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims description 3
- 229960003407 pegaptanib Drugs 0.000 claims description 3
- 229960003876 ranibizumab Drugs 0.000 claims description 3
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims description 3
- 229950000578 vatalanib Drugs 0.000 claims description 3
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 claims description 2
- 230000000172 allergic effect Effects 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 208000037916 non-allergic rhinitis Diseases 0.000 claims description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 4
- 239000002525 vasculotropin inhibitor Substances 0.000 claims 2
- 238000003556 assay Methods 0.000 abstract description 9
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 abstract description 2
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 abstract 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 abstract 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 description 66
- 102000039446 nucleic acids Human genes 0.000 description 61
- 108020004707 nucleic acids Proteins 0.000 description 61
- 102000005962 receptors Human genes 0.000 description 49
- 108020003175 receptors Proteins 0.000 description 49
- 108090000623 proteins and genes Proteins 0.000 description 46
- 230000000692 anti-sense effect Effects 0.000 description 40
- 210000001519 tissue Anatomy 0.000 description 37
- 208000037062 Polyps Diseases 0.000 description 32
- 238000010186 staining Methods 0.000 description 27
- 125000003729 nucleotide group Chemical group 0.000 description 26
- 244000097202 Rathbunia alamosensis Species 0.000 description 25
- 235000009776 Rathbunia alamosensis Nutrition 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 25
- 239000002773 nucleotide Substances 0.000 description 25
- 101150054147 sina gene Proteins 0.000 description 25
- 230000006870 function Effects 0.000 description 24
- 210000000981 epithelium Anatomy 0.000 description 20
- 201000010099 disease Diseases 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- 238000012360 testing method Methods 0.000 description 18
- 206010020718 hyperplasia Diseases 0.000 description 17
- 230000010261 cell growth Effects 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 230000000295 complement effect Effects 0.000 description 15
- 238000001727 in vivo Methods 0.000 description 15
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 15
- 101800003838 Epidermal growth factor Proteins 0.000 description 14
- 102400001368 Epidermal growth factor Human genes 0.000 description 14
- 229940116977 epidermal growth factor Drugs 0.000 description 14
- 230000009368 gene silencing by RNA Effects 0.000 description 13
- 108020004999 messenger RNA Proteins 0.000 description 13
- 239000003102 growth factor Substances 0.000 description 11
- 210000001552 airway epithelial cell Anatomy 0.000 description 10
- -1 phospho Chemical class 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000002390 hyperplastic effect Effects 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 239000005557 antagonist Substances 0.000 description 8
- 229940125715 antihistaminic agent Drugs 0.000 description 8
- 239000000739 antihistaminic agent Substances 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 229940125389 long-acting beta agonist Drugs 0.000 description 8
- 102000040430 polynucleotide Human genes 0.000 description 8
- 108091033319 polynucleotide Proteins 0.000 description 8
- 239000002157 polynucleotide Substances 0.000 description 8
- 210000001944 turbinate Anatomy 0.000 description 8
- PZSMUPGANZGPBF-UHFFFAOYSA-N 4-[5-(dithiolan-3-yl)pentanoylamino]butanoic acid Chemical compound OC(=O)CCCNC(=O)CCCCC1CCSS1 PZSMUPGANZGPBF-UHFFFAOYSA-N 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- 108091030071 RNAI Proteins 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000002452 interceptive effect Effects 0.000 description 7
- 239000002679 microRNA Substances 0.000 description 7
- 239000003226 mitogen Substances 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 108700011259 MicroRNAs Proteins 0.000 description 6
- 208000000592 Nasal Polyps Diseases 0.000 description 6
- 108010029485 Protein Isoforms Proteins 0.000 description 6
- 102000001708 Protein Isoforms Human genes 0.000 description 6
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000000540 analysis of variance Methods 0.000 description 6
- 239000000090 biomarker Substances 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000006711 vascular endothelial growth factor production Effects 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 5
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 5
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 5
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 5
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 5
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 5
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 102100035194 Placenta growth factor Human genes 0.000 description 5
- 108010009583 Transforming Growth Factors Proteins 0.000 description 5
- 102000009618 Transforming Growth Factors Human genes 0.000 description 5
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229940126864 fibroblast growth factor Drugs 0.000 description 5
- 230000030279 gene silencing Effects 0.000 description 5
- 102000058223 human VEGFA Human genes 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 229960005127 montelukast Drugs 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 150000003431 steroids Chemical class 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 108090000994 Catalytic RNA Proteins 0.000 description 4
- 102000053642 Catalytic RNA Human genes 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 4
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 4
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 4
- 238000012313 Kruskal-Wallis test Methods 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000001516 cell proliferation assay Methods 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 108091092562 ribozyme Proteins 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000007790 scraping Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 102000000412 Annexin Human genes 0.000 description 3
- 108050008874 Annexin Proteins 0.000 description 3
- 108020005544 Antisense RNA Proteins 0.000 description 3
- 108091033380 Coding strand Proteins 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 3
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108010001498 Galectin 1 Proteins 0.000 description 3
- 102100021736 Galectin-1 Human genes 0.000 description 3
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 3
- 108091028664 Ribonucleotide Proteins 0.000 description 3
- 108091027967 Small hairpin RNA Proteins 0.000 description 3
- 208000024780 Urticaria Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000002469 basement membrane Anatomy 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000003184 complementary RNA Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 108091070501 miRNA Proteins 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 230000001613 neoplastic effect Effects 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 230000001686 pro-survival effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 206010039083 rhinitis Diseases 0.000 description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 3
- 239000002336 ribonucleotide Substances 0.000 description 3
- 125000002652 ribonucleotide group Chemical group 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 210000003556 vascular endothelial cell Anatomy 0.000 description 3
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 102000004121 Annexin A5 Human genes 0.000 description 2
- 208000037874 Asthma exacerbation Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 2
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 2
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000014429 Insulin-like growth factor Human genes 0.000 description 2
- 102000012355 Integrin beta1 Human genes 0.000 description 2
- 108010022222 Integrin beta1 Proteins 0.000 description 2
- 101100042271 Mus musculus Sema3b gene Proteins 0.000 description 2
- 102000002111 Neuropilin Human genes 0.000 description 2
- 108050009450 Neuropilin Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000028347 Sinus disease Diseases 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 2
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 2
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 2
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 208000002352 blister Diseases 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 230000001680 brushing effect Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000013129 endoscopic sinus surgery Methods 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 210000005081 epithelial layer Anatomy 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000012226 gene silencing method Methods 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 210000004086 maxillary sinus Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 230000017095 negative regulation of cell growth Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 229940124624 oral corticosteroid Drugs 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 210000003695 paranasal sinus Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 229960002052 salbutamol Drugs 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 230000007838 tissue remodeling Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000013042 tunel staining Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 208000036065 Airway Remodeling Diseases 0.000 description 1
- 244000036975 Ambrosia artemisiifolia Species 0.000 description 1
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 1
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 241000238657 Blattella germanica Species 0.000 description 1
- 241001674044 Blattodea Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- 241001149956 Cladosporium herbarum Species 0.000 description 1
- 244000052363 Cynodon dactylon Species 0.000 description 1
- 241000238710 Dermatophagoides Species 0.000 description 1
- 241000238740 Dermatophagoides pteronyssinus Species 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000000579 Epigen Human genes 0.000 description 1
- 108010016906 Epigen Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001067189 Homo sapiens Plexin-A1 Proteins 0.000 description 1
- 101001067187 Homo sapiens Plexin-A2 Proteins 0.000 description 1
- 101001067184 Homo sapiens Plexin-A3 Proteins 0.000 description 1
- 101001067178 Homo sapiens Plexin-A4 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000209082 Lolium Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 229940083963 Peptide antagonist Drugs 0.000 description 1
- 102100034382 Plexin-A1 Human genes 0.000 description 1
- 102100034381 Plexin-A2 Human genes 0.000 description 1
- 102100034386 Plexin-A3 Human genes 0.000 description 1
- 102100034385 Plexin-A4 Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000223892 Tetrahymena Species 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 108010034265 Vascular Endothelial Growth Factor Receptors Proteins 0.000 description 1
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 1
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000005058 airway cell Anatomy 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001042 autoregulative effect Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000011072 cell harvest Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000009956 central mechanism Effects 0.000 description 1
- 208000004711 cerebrospinal fluid leak Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012611 container material Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000002674 endoscopic surgery Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000006718 epigenetic regulation Effects 0.000 description 1
- 230000008556 epithelial cell proliferation Effects 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 230000008508 epithelial proliferation Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000017819 hyperplastic polyp Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940125369 inhaled corticosteroids Drugs 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000035168 lymphangiogenesis Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 208000016366 nasal cavity polyp Diseases 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940127249 oral antibiotic Drugs 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 102000002022 plexin Human genes 0.000 description 1
- 108050009312 plexin Proteins 0.000 description 1
- 208000014003 polyp of maxillary sinus Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000003133 propidium iodide exclusion Methods 0.000 description 1
- 238000001814 protein method Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000006807 siRNA silencing Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- YZHUMGUJCQRKBT-UHFFFAOYSA-M sodium chlorate Chemical compound [Na+].[O-]Cl(=O)=O YZHUMGUJCQRKBT-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000003718 sphenoid sinus Anatomy 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- CRSwNP hyperplastic sinonasal polyposis
- TGF ⁇ transforming growth factor ⁇
- FGF fibroblast growth factor
- VEGF vascular endothelial cell growth factor
- FIG. 1 shows a companson of soluble growth factors in nasal lavages of untreated CRSwNP, CRSwNP patients at 1 month post operatively, CRS alone, and normal control subjects VEGF and EGF in nasal lavages were assayed according to manufacturer's instruction (antibodies and kits from R&D Systems) The lower limit of detection was 5 pg/ml Values represent the mean +/ SEM ' ⁇ p ⁇ 0 001 vs Control, CRS alone, or CRSwNP post op subjects by Kruskal Walhs Test Human subjects data is shown in Table 1
- FIG. 2 shows that VEGF is over expressed by epithelial cells in sinonasal tissue
- Fig. 2B shows flow cytometric analysis of cell surface VEGF on cultured PNEC (primary nasal epithelial cells) from normal control and CRSwNP subjects
- Fig. 2C shows soluble VEGF isoforms 165 and 121 in cell supernatents of PNEC, measured by ELISA according to manufacturers instructions (R&D) Lower limit of detection was 5 pg/ml x p ⁇ 0 05 and * x p ⁇ 0 02 vs Control subject by Kruskal Wallis Test
- FIG. 3 shows that receptors for VEGF are abundantly expressed by epithelial cells in sinonasal tissue
- Figure 4 shows that primary nasal epithelial cells (PNEC) from CRSwNP subjects display faster growth rates in vitro
- Fig. 4A shows a compa ⁇ son of time to confluence of cultures of PNEC from normal control and CRSwNP subjects PNEC from normal control and CRSwNP subjects were cultured as described in Methods. Results are expressed as # days to confluency of culture from day of seeding into 6 well plates and assessed in triplicate Fig.
- 4B shows a compa ⁇ son of cell proliferation rates of PNEC from normal control and CRSwNP subjects
- Cell number was determined by normalization of DNA content to a standard curve using Cyquant cell proliferation assay as described in Methods
- Each circle indicates an experiment from a single donor Bars represent the mean *p ⁇ 0 008 or **p ⁇ 0 005 vs control group by Kruskal Wallis Test
- Figure 5 shows that sinonasal epithelial cell growth is VEGF dependent
- Fig. 5A shows the effects of anti-VEGF antibody and recombinant EGF exposure on growth rates of PNEC from CRSwNP subjects
- Fig. 5B shows the effects of anti-NPl , anti- VEGFRl (vascular endothelial cell growth factor 1), and anti-VEGFR2 (vascular endothelial cell growth factor 2) antibody exposures on growth rates of PNEC from CRSwNP subjects
- Fig. 5A shows the effects of anti-VEGF antibody and recombinant EGF exposure on growth rates of PNEC from CRSwNP subjects
- Fig. 5B shows the effects of anti-NPl , anti- VEGFRl (vascular endothelial cell growth factor 1), and anti-VEGFR2 (vascular endothelial cell growth factor 2) antibody exposures on growth rates of PNEC from CRSwNP subjects
- Fig. 5A shows the effects of anti-VEGF antibody and recomb
- 5C shows the effects of combination of anti-NPl , anti-VEGFRl , and anti-VEGFR2 antibody exposures on growth rates of PNEC from CRSwNP subjects
- PNEC from CRSwNP subjects were seeded at 5000 cells/well of a 96 well plate and exposed to designated blocking antibodies, recombinant EGF (R&D Systems) or IgG control antibody as described in Methods
- Cell number was determined after normalization of DNA fluorescence to a standard curve using Cyquant cell proliferation assay as described in Methods
- Each curve represents the mean of 5 expenments, each from an individual CRSwNP donor
- Each condition and time point was measured in quadruplicate SEM ranged between 12-27% of the mean ⁇ p ⁇ 0 05, or *"p ⁇ 0 02, vs Control condition at 96 hours by ANOVA and post hoc Bonferroni
- Results in the Fig. 6A are expressed as mean +/-SEM of % cells staining positive for annexin Fig.
- 6B shows light microscopic views of PNEC under 2OX power
- White arrows point to cell membrane blebs *p ⁇ 0 001, "p ⁇ 0 02, or x ⁇ >: p ⁇ 0 05 vs Control condition by ANOVA and post hoc Bonferroni Test
- FIG. 8C shows realtime PCR analysis of NPl mRNA Panel
- VEGF is a central pathway by which airway epithelial cell growth is regulated
- nasal lavage aspirates (2) surgical sinonasal tissue, and (3) cultured primary nasal airway epithelial cells
- VEGF-A the VEGF-A receptors
- VEGF receptor 1 VEGF receptor 1
- VGFR2 VEGF receptor 2
- NPl neuropilin-1
- One aspect of the invention is a method for inhibiting the proliferation of epithelial cells, comp ⁇ sing contacting the cells with an effective amount of an inhibitor of the expression of and/or of the activity of VEGF A, and/or VEGFRl , and/or VEGFR2, and/or NPl
- VEGF-A family such as the VEGF isoforms (splice variants), VEGF 165, VEGF 121, or VEGF 189, or the homologs, VEGF-B, VEGF-C, VEGF-D, or P/GF (placental growth factor)
- VEGFR3 and NP2 which are known to interact with some of the molecules noted above, can also serve as targets
- NPl is known to engage other ligands or co-receptors, which are also expected to be involved in the proliferation of epithelial cells and which can thus be inhibited by a method of the invention
- additional proteins include,
- the epithelial cells whose growth is inhibited by a method of the invention can be in vitro, in cell culture
- These cells can be primary cell cultures, or cells from an established cell line (e g , BEAS2B, A549 or 16HBE cells, all of which are available from the American Type Culture Collection, Manassas, VA)
- the epithelial cells whose growth (hyperplasia) is inhibited can be in vivo, in a subject (e.g , a subject having a chronic inflammatory respiratory disorder)
- a subject e.g , a subject having a chronic inflammatory respiratory disorder
- One embodiment of this latter method is a method for treating a subject having a chronic inflammatory respiratory disorder, or for preventing the development of such a disorder, comp ⁇ sing administering to the subject an effective amount of an inhibitor of the expression of, and/or of the activity of, VEGF-A, and/or VEGFRl, and/or VEGFR2, and/or NPl
- chronic inflammatory respiratory disorder that can be treated by a method of the invention are, e.g , chronic rhinosinusitis with nasal polyposis (CRSwNP), chronic rhinosinusitis without nasal polyposis, asthma (in adults or a pediatric population), chronic obstructive pulmonary disease (COPD), allergic and/or nonallergic rhinitis, or allergic bronchopulmonary aspergillosis, or cystic fibrosis All of these disorders are airway inflammatory disorders, for which dysfunctional airway epithelial cells are central
- a method of the invention targets these disturbed epithelial cells At least some of these condtions, including asthma, exhibit a histological appearance and behavior (recurrences and exacerbations) that are identical to that of CRSwNP It is expected that cystic fibrosis, another airway inflammatory disorder, can also be treated by a method of the invention
- an inhibitor of the invention can be, e g , an antibody or antibody fragment, an inhibitory RNA (siRNA, microRNA, etc), a small molecule, a peptide, or the like
- the inhibitor comprises an antibody (e g , a blocking antibody) against VEGF, NP-I, VEGFRl , VEGFR2, or combinations thereof
- the inhibitor comprises a blocking antibody against other combinations of the proteins noted above
- the inhibitor can comprise a blocking antibody against
- VEGF A in combination with one or more of VEGFRl, VEGFR2 and VEGFR3, (2) NPl in combination with one of more of VEGFRl , VEGFR2, VEGFR3, integrin beta-1 , TGF beta-1, FGF2, FGF4, hepatocyte growth factor/scatter factor, and galectin-1,
- NP2 in combination with one or more of VEGFRl , VEGFR2, VEGFR3, integ ⁇ n beta-1, TGF beta-1, FGF2, FGF4, hepatocyte growth factor/scatter factor, and galectin-1 ,
- NPl in combination with VEGF-A, (5) NP2 in combination with VEGF-A, or
- VEGF-A (NPl or NP2), and (VEGFRl or VEGFR2),
- an anti-VEGF blocking antibody means one or more anti-VEGF blocking antibodies, which can be the same or different
- the inhibitor is an RNA aptamer, such as pegaptamb, a partial or full-length antibody, such as ranibizumab or bevacizumab, a VEGF receptor decoy, such as VEGF Trap (see, e g , USP 7,541 ,172), small interfering RNA-based therapies, such as a microRNA or an siRNA, including the siRNAs described herein, microRNAs, bevasiranib, or AGN21 1745, a tyrosine kinase inhibitor, such as vatalamb, pazopanib, TG 100801, TGlOl 095, AG013958 or AL39324, a small molecule, or a blocking peptide
- a blocking peptide against the VEGF receptors NPl and/or VEGFR2 such as those desc ⁇ bed in Barr et al (2005) Br J Cancer 92, 328-333
- An inhibitor of the invention can be administered by, e g , systemic intravenous (IV) or by an intranasal route
- the method comprises screening putative inhibitory agents for their ability to inhibit the growth of suitable epithelial cells in culture (such as cultured primary nasal epithelial cells (PNEC), primary bronchial epithelial cells (PBEC), or suitable established cell lines, such as BEAS2B, A549 or 16HBE cells)
- suitable epithelial cells in culture such as cultured primary nasal epithelial cells (PNEC), primary bronchial epithelial cells (PBEC), or suitable established cell lines, such as BEAS2B, A549 or 16HBE cells
- PNEC cultured primary nasal epithelial cells
- PBEC primary bronchial epithelial cells
- suitable established cell lines such as BEAS2B, A549 or 16HBE cells
- cell growth can be assayed by any of a va ⁇ ety of methods, including, e g , using Cyqyant dye or BUdR
- putative inhibitory agents are screened for their ability to induce apoptosis of such epit
- kits for treating a subject having a chronic inflammatory respiratory disorder, or for preventing the development of such a condition comp ⁇ sing a) an effective amount of an inhibitor of the expression of, and/or the activity of, VEGF
- the kit can comprise applicators that are suitable for administering the agent as a nasal spray or as a topical lavage (nasal wash solution, for bathing the sinuses and nose with the agent)
- VEGF A which is sometimes referred to as VEGF
- VEGF C vascular endothelial growth factor
- VEGF-D vascular endothelial growth factor
- P/GF placental growth factor
- VEGF-A receptor is a receptor which VEGF A binds to and subsequently activates Such receptors include, e g , NP-I , VEGFRl (FIt-I) and VEGFR2 (FIk- 1/KDR)
- a "subject,” as used herein, can refer to any animal which is subject to a chronic inflammatory respiratory disorder, e g , a mammal, such as an experimental animal, a farm animal, pet, or the like
- the animal is a primate, preferably a human
- An "effective amount" of an inhibitor of the invention is an amount that is effective to elicit a measurable amount of biological activity, e g a measurable amount of suppression or inhibition of VEGF-A mediated proliferation of epithelial cells, or inhibition of a chronic inflammatory respiratory disorder
- an effective amount of an inhibitor of the invention does not elicit substantial amounts of undesirable (e g , toxic) effects
- the suppression or inhibition can occur prophylactically (e g , preventively, to inhibit the development of the disorder), or in a subject who already has the condition
- treatment with an inhibitor of the invention can ameliorate one or more symptoms of the condition
- va ⁇ ety of types of agents can be used to inhibit the expression or activity of, e g , VEGF-A or a VEGF-A receptor in a method of the invention
- An "inhibitor" of expression or activity is an agent that reduces the expression or activity by a detectable amount
- the inhibitory agent inhibits the expression of VEGF-A or a VEGF A receptor
- expression refers to any aspect of the process by which information in a gene is converted to a functional molecule, e g , any aspect of transcription or translation of the gene
- expression can refer to transcription, post-transc ⁇ ptional processing, translation, or post-translational processing
- inhibitors of expression include an antisense nucleic acid, a nbozyme, a microRNA, or a small interfering RNA (siRNA), which is specific for a nucleic acid encoding VEGF-A or a VEGF-A receptor
- siRNA small interfering RNA
- nucleic acid sequences encoding VEGF-A and its receptors are well-known in the art For example, one can access sequences encoding these proteins in publically available databases, such as the GenBank database operated by the NCBI The GenBank accession numbers and sequences for some suitable targets are presented in Table 2 and in the Sequence Listing herein
- accession numbers in conjunction with the names and unique gene symbols of the genes, is adequate to unambiguously identify these genes
- sequences were obtained from the GenBank database (at the world wide web site ncbi nlm nih gov/Genbank), and the GenBank Accession Numbers (e g , NM numbers) are provided in Table 2 and in the Sequence Listing Note that the sequences that are presented herein are correct as of the day of filing of this application However, in GenBank, sequences are periodically updated by the NCBI to correct errors As the sequences are curated, and new sequences replace previous sequences that contained errors, the replacement is descnbed in the COMMENT section of the GenBank entry Sequences that are subsequently corrected are encompassed by the present application At any given time, only a single sequence is associated with
- the antisense nucleic acid may be, e g , an oligonucleotide, or a nucleic acid comprising an antisense sequence that is operably linked to an expression control sequence, and that is expressed in the cell
- antisense nucleic acids to downregulate the expression of a particular protein in a cell is well known in the art See, e g , Weintraub et al (1986) Reviews Trends in Genetics 1(1), Askan et al (1996) JV Eng J Med 334, 316-318, Bennett et al (1995) Circulation 92, 1981 1993, Mercola et al (1995) Cancer Gene Ther 2, 47 59, Rossi et al (1995) Br Med Bull 51 217 225, or Wagner, R W (1994) Nature 372, 333-335
- An antisense nucleic acid molecule may comprise a nucleotide sequence that is complementary to the coding strand of another nucleic acid molecule (e g , an mRNA sequence), or to a portion thereof, and accordingly is capable of hydrogen bonding to the coding strand of the other nucleic acid molecule
- antisense sequences can be complementary to a sequence found in the 5' or 3' untranslated region of
- the antisense nucleic acid can be complementary in sequence to a regulatory region of the gene encoding the mRNA, for instance a transcription initiation sequence or regulatory element, or a splice site
- an antisense nucleic acid is designed so as to be complementary to a region preceding or spanning the initiation codon on the coding strand or in the 3' untranslated region of an mRNA
- An antisense nucleic acid for inhibiting the expression of a protein of interest in a cell can be designed based upon the nucleotide sequence encoding the protein or upon sequences regulating its transcription or translation, constructed according to the rules of Watson and Crick base pairing
- antisense molecules that are complementary to a region of a gene involved in transcription (thereby blocking transcription and/or the production of isoforms, such as splice variants), see, e g, Lee et al (1979) Nucl Acids Res 6, 3073, Cooney et al (1988) Science 24J_, 456, and Dervan et al ( 1991) Science 25_L 1360
- antisense see, e g , U S Pat Nos 6,200,960, 6,200,807, 6, 197,584, 6,190,869, 6,190,661 , 6, 187,587, 6, 168,950, 6,153,595, 6,150,162, 6, 133,246, 6, 1 17,847, 6,096,722, 6,087,343, 6,040,296, 6,005,095, 5,998,383, 5,994,230, 5,891 ,725, 5,885,970, and 5,840,708
- An antisense nucleic acid can exist
- Antisense nucleic acids can be constructed using chemical synthesis procedures known in the art Such an antisense nucleic acid can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e g phosphorothioate de ⁇ vatives and ac ⁇ dine substituted nucleotides can be used To inhibit expression of VEGF A or a VEGF A receptor in cells in culture, such antisense nucleic acids can be added to cells in culture media Typically, synthetic oligonucleotides are added to a final concentration of about 1OnM to about 100OnM, preferably about 50 nM to about 200 nM ⁇ e g , about 200 ⁇ g ohgonucleotide/ml)
- an antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense onentation ( ⁇ e , nucleic acid transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest)
- Expression control sequences e g , regulatory sequences
- operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the expression of the antisense RNA molecule in a cell of interest
- promoters and/or enhancers or other regulatory sequences can be chosen which direct constitutive, tissue specific or inducible expression of antisense RNA Inducible expression of antisense RNA, regulated by an inducible eukaryotic regulatory system, such as the Tet system ⁇ e g , as described in Gossen et al (1992) Proc Natl Acad Sci USA 89, 5547 5551 , Gossen et al (19
- an inhibitory agent of the invention is a nbozyme
- Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a smgle- stranded nucleic acid, such as an mRNA, to which they have a complementary region
- Ribozymes see e g , Ohkawa et al ( 1995) J Biochem 1 18, 251-258, NASAdsson et al (1995) Trends Bwtechnol ⁇ 3_, 286-289, Rossi, J J (1995) Trend:, Biotethnol Vi, 301-306, Kiehntopf et al (1995) J MoI Med 73, 65 71 )
- a nbozyme having specificity for an mRNA of interest can be designed based upon the nucleotide sequence of , e g , the corresponding cDNA For example, a de ⁇ vative of a Tetrahymen
- the inhibitor is an siNA (a double-stranded nucleic acid, preferably an RNA, which is sometimes referred to as a small or short, interfering or inhibitory, nucleic acid
- the nucleic acid is an RNA
- the molecule is sometimes referred to as an siRNA
- siNA a double-stranded nucleic acid
- the molecule is sometimes referred to as an siRNA
- the siRNA can comprise a single-stranded polynucleotide represented by one of the following sequences that are desc ⁇ bed in the Examples herein CCACAUUUCACAAGAAGAUUGUGCA (SEQ ID NO 1), UGCACAAUCUUCUUG
- an “active" fragment or va ⁇ ant refers to a fragment or vanant of one of the preceding nucleic acids (SEQ ID NOs 1-6) which retains at least one activity of that nucleic acid (e g , the ability to suppress the expression of VEGF-A or a VEGF-A receptor, and/or to inhibit a chronic inflammatory respiratory disorder)
- nucleic acids comprising small substitutions, additions, deletions, etc, are tolerated provided they retain such an activity
- Nucleic acids that exhibit at least about 90% (e g , at least about 95%, or at least about 98%) sequence identity to a nucleic acid of interest, or to an active fragment thereof, are also included Methods for determining if a nucleic acid exhibits a particular percent identity to a nucleic acid are conventional
- a "complement" of a nucleic acid refers to a complete complement
- siNA is meant to be equivalent to other terms used to describe nucleic acid molecules that are capable of mediating sequence specific RNAi (RNA interference), for example short (or small) interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), short hairpin RNA (shRNA), short interfenng oligonucleotide, short interfenng nucleic acid, short interfenng modified oligonucleotide, chemically-modified siRNA, post-transcnptional gene silencing RNA (ptgsRNA), translational silencing, and others Long double-stranded interfenng RNAs, such as miRNAs, appear to tolerate mismatches more readily than do short double-stranded RNAs
- RNAi is meant to be equivalent to other terms used to descnbe sequence-specific RNA interference, such as post-transcnptional gene silencing, or epigen
- An siNA can be designed to target any region of the coding or non-coding sequence of a gene.
- An siNA is a double-stranded polynucleotide molecule comprising self-complementary sense and antisense regions, wherein the antisense region comprises nucleotide sequence that is complementary to nucleotide sequence in a target nucleic acid molecule or a portion thereof and the sense region has a nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof
- the siNA can be assembled from two separate oligonucleotides, where one strand is the sense strand and the other is the antisense strand, wherein the antisense and sense strands are self-complementary
- the siNA can be assembled from a single oligonucleotide, where the self-complementary sense and antisense regions of the siNA are linked by means of a nucleic acid based or non-nucleic acid-based hnker(s)
- the short interfering nucleic acid molecules of the invention lack 2'-hydroxy (2'- OH) containing nucleotides
- short interfering nucleic acids do not require the presence of nucleotides having a 2'-hydroxy group for mediating RNAi and as such, short interfering nucleic acid molecules of the invention optionally do not include any ribonucleotides (e g , nucleotides having a 2'-OH group)
- siNA molecules that do not require the presence of ribonucleotides within the siNA molecule to support RNAi can however have an attached linker or linkers or other attached or associated groups, moieties, or chains containing one or more nucleotides with 2'-OH groups
- siNA molecules can comp ⁇ se ribonucleotides at about 5, 10, 20, 30, 40, or 50% of the nucleot
- siNAs are conventional and will be evident to the skilled worker.
- In vitro methods include, e.g., processing the VEGF-A or VEGF-A receptor ribopolynucleotide sequence in a cell-free system (e.g., digesting long double-stranded RNAs with RNAse III or Dicer), transcribing recombinant double-stranded VEGF-A or VEGF-A receptor DNA in vitro, and chemical synthesis of nucleotide sequences homologous to a VEGF- A or VEGF-A receptor sequence. See, e.g., Tuschl et al. (1999) Genes & Dev. B .
- In vivo methods include, e.g., (1) transfecting DNA vectors into a cell such that a substrate is converted into siRNA in vivo [see, e.g., Kawasaki et al. (2003) Nucleic Acids Res 3_1_, 700-707; Miyagishi et al. (2003) Nature Biotechnol 20, 497-500; Lee et al. (2002) Nature Biotechnol 20, 500-505, Brummelkamp et al. (2002) Science 296, 550-553; McManus et al. (2002) RNA 8, 842-850; Paddison et al.
- siRNA 1 milligram of siRNA, which is sufficient for about 1000 transfection experiments using a 24- well tissue culture plate format.
- one or more siRNAs can be added to cells in culture media, typically to a final concentration of about 50-200 ⁇ g, preferably about 50 ⁇ g siRNA/ml.
- Any of a variety of conventional methods can be used to introduce siNAs into cells, including transfection, electroporation, or other methods known in the art. See, e.g., Hannon (2002) Nature 418, 244-251 ; Bernstein et al. (2002) RNA 7, 1509-1521 ; Hutvagner et al, Curr. Opin.
- RNA interference both in vitro and in vivo
- methods of designing and preparing siRNAs, testing them for efficacy, and using them in methods of RNA interference see, e g , Allshire (2002) Science 297, 1818- 1819, Volpe et al (2002) Science 297, 1833-1837, Jenuwein (2002) Science 297, 2215-2218, Hall et al (2002) Science 297 2232-2237, Hutvagner et al (2002) Science 297, 2056-60, McManus et al (2002) RNA 8, 842-850, Reinhart et al (2002) Gene & Dev 16.
- Ribozymes and siRNAs can take any of the forms, including modified versions, described above for antisense nucleic acid molecules
- an interfering nucleic acid is a double-stranded RNA (e g , an siRNA), one of whose strands comprises (or consists essentially of) one of the sequences represented by SEQ ID NOS 1 -6, or an active variant thereof, or a complement of one of those sequences
- an antisense nucleic acid or siRNA may be of any length that is effective for inhibition of a gene of interest
- an antisense nucleic acid is between about 6 and about 50 nucleotides (e g , between about 10 and 30 nucleotides, or at least about 12, 15, 20, 25, 30, 35, 40, 45 or 50 nt), and may be as large as about 100 to about 200 nucleotides, or larger
- Antisense nucleic acids having about the same length as the gene or coding sequence to be inhibited may be used
- the length of an effective MRNA IS generally between about 19 bp and about 29 bp in length, (e g , about 19,
- consists essentially of when used in the context of biopolymers, refers to a sequence which is intermediate between the specific number of residues (amino acids or nucleotides) encompassed by the term “consisting of” and the longer unspecified length encompassed by the term “comprising " Residues in addition to the residues encompassed by “consisting of” language do not affect the basic and novel characteristics (e g , in the present case, the ability to inhibit VEGF-A or VEGF-A receptor expression and/or activity) of the molecule encompassed by the "consisting of" language
- an inhibitory nucleic acid such as an antisense molecule, a ⁇ bozyme (the recognition sequences), or an siRNA, comprises a strand that is complementary (100% identical in sequence) to a sequence of a gene that it is designed to inhibit
- 100% sequence identity between the nucleic acid and the target gene is not required to practice the present invention
- the variants may be artificially generated Nucleic acid sequences with, e g , small insertions, deletions, and single point mutations relative to the target sequence can be effective for inhibition
- the degree of sequence identity may be optimized by sequence comparison and alignment algorithms known in the art (see G ⁇ bskov and Devereux, Sequence Analysis Primer, Stockton Press, 1991, and references cited therein) and calculating the percent difference between the nucleotide sequences by, for example, the Smith-Waterman algorithm as implemented in the BESTFIT software program using default parameters (e g , University of Wisconsin Genetic Computing Group) Greater than about 90% sequence identity (e g , about 95%, 98% or 99%), or even 100% sequence identity, between the inhibitory nucleic acid and the portion of the target gene is preferred
- an active va ⁇ ant of an inhibitory nucleic acid of the invention is one that hybridizes to the sequence it is intended to inhibit under conditions of high stringency
- the duplex region of an siRNA may be defined functionally as a nucleotide sequence that is capable of hybridizing with a portion of the target gene transc ⁇ pt under high st ⁇ ngency conditions (e g , 400 rnM NaCl, 40 mM PIPES pH 6 4, 1 mM EDTA, 70°C hybridization for 12-16 hours, or equivalent conditions), followed generally by washing
- a skilled worker can readily test a candidate siRNA or antisense va ⁇ ant molecule to determine if it is inhibitory
- RNA or DNA is one that is in a form not found in its original environment or in nature, e g , more concentrated, more purified, separated from at least one other component with which it is naturally associated, in a buffer, etc
- the inhibitory agent inhibits an activity of the VEGF-A or a
- inhibitors of activity include, e g , an antibody specific for VEGF-A or VEGF A receptor, a peptide or oligonucleotide which binds to the polypeptide of interest and effectively eliminates its function, or a small molecule pharmaceutical agent
- Another potential antagonist is a closely related protein which binds to a VEGF receptor but inhibits its function rather than activating it
- an antagonist of VEGFR2 receptor could be a protein that is closely related to VEGFR2, but is an inactive form of the polypeptide and thereby prevents the action of VEGFR2
- these antagonists include a negative dominant mutant of the VEGFR2 polypeptide, wherein one chain of the hetero dimeric form of VEGFR2 is dominant and is mutated such that biological activity is not retained
- An example of a negative dominant mutant includes a truncated version of a dime ⁇ c VEGFR2 which is capable of interacting with another dimer to form wild type VEGFR2,
- an antibody which is generated against a protein molecule or a peptide fragment of VEGF-A or a VEGF A receptor
- antibody is used in the broadest sense and encompasses single monoclonal antibodies, polyclonal antibodies, chimenc antibodies, humanized antibodies, single-chain antibodies and antibody fragments (e g , Fab, F(ab'), Fv)
- Antibodies are designed to block the activity of VEGF A or a VEGF A receptor, e g as it relates to the stimulation of hyperplastic epithelium in sinonasal polyp tissue
- a 'blocking"antibody or a "neturahzing" antibody as used herein, means an antibody that can inhibt the function of a defined target of interest
- the antibodies can be produced by standard antibody technologies (e g , monoclonal antibody technologies) and can be humanized if successful in blocking the VEGF-A or VEGF-A receptor activity If desired, candidate
- Another class of agents that inhibit the function of VEGF-A or a VEGF-A receptor are small molecules which bind to and occupy the active site of the polypeptide, thereby making the catalytic suite inaccessible to substrate wuch the normal biological activity is prevented
- small molecules include, e g , small peptides or peptide-hke molecules, and small organic compounds, which can include both synthetic compounds and naturally occurring compounds
- a number of inhibitors of the expression or the activity of VEGF-A or a VEGF A receptor have been proposed and/or developed for the treatment of conditions which are mediated by VEGF other than chronic inflammatory respiratory disorders
- Such conditions include, e g , anti-tumor therapies, treatment of macular degeneration, and of other conditions mediated by angiogenesis It is expected that such agents would also be effective against chronic inflammatory respiratory disorders such as CRSwNP It might be necessary to modify the formulations, dosages and routes of administration of these agents in order to optimize the treatment of chronic inflammatory respiratory disorders Suitable modifications would be evident
- RNA aptamer such as pegaptanib, a partial or full-length antibody, such as rambizumab or bevacizumab, a VEGF receptor decoy, such as VEGF Trap (see, e g , USP 7,541,172), small interfering RNA-based therapies, such as a microRNA or an siRNA, including the siRNAs desc ⁇ bed herein, microRNAs, bevasiramb, or AGN21 1745, a tyrosine kinase inhibitor, such as vatalanib, pazopamb, TG 100801, TG 1O1O95, AG013958 or AL39324, or a blocking peptide
- a blocking peptide against the VEGF receptors NPl and/or VEGFR2 such as described in Barr et al (2005) Br J Cancer 92, 328-333 A number of considerations are generally taken
- siRNAs e g , plasmid vectors, retrovirus vectors, including oncoretrovirus vectors and lentivirus vectors, and hydrodynamic "high pressure" delivery
- an inhibitory agent when treating a subject, is administered by systemic intravenous (IV) or by a local intranasal route, such as an intranasal spray, a metered dose inhaler, a nebulizer, or a dry powder inhaler
- IV systemic intravenous
- a local intranasal route such as an intranasal spray, a metered dose inhaler, a nebulizer, or a dry powder inhaler
- Formulations for delivery by a particular method e g , solutions, buffers, and preservatives, as well as droplet or particle size for intranasal administration
- the aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen or the like
- the dose of an agent of the invention, or composition thereof, administered to an animal, particularly a human, in the context of the present invention should be sufficient to effect at least a detectable amount of a therapeutic response in the
- the dose administered is an "anti inflammatory effective amount or an "anti proliferative effective amount '
- One skilled in the art can easily determine the appropriate dose, schedule, and method of administration for the exact formulation of the composition being used, in order to achieve the desired response in the individual patient
- One embodiment of the invention is a kit useful for any of the methods disclosed herein
- kits of the invention can comp ⁇ se one or more isolated inhibitors of the invention
- a device, composition, or other means for administering the inhibitor to the nasal tract can also be included
- a kit suitable for a therapeutic treatment in a subject may further compnse a pharmaceutically acceptable carrier and, optionally, a container or packaging material
- kits of the invention can be used in experiments, e g to study mechanisms by which VEGF acts as an epithelial cell mitogen, etc
- a skilled worker will recognize components of kits suitable for carrying out any of the methods of the invention
- kits comprise instructions for performing the method, and/or a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products (such as the FDA), which notice reflects approval by the agency of manufacture, use or sale for human administration
- agents in a kit of the invention may comprise other therapeutic compounds, for combination therapy
- kits of the invention include suitable buffers, pharmaceutically acceptable carriers, or the like, containers, or packaging matenals
- the reagents of the kit may be in containers in which the reagents are stable, e g , in lyophihzed form or stabilized liquids
- the reagents may also be in single use form, e g , in single dosage form for use as therapeutics, or in single reaction form for diagnostic use
- CRSwNP patients were defined by historical, endoscopic, and radiographic criteria, and by meeting the definition of the Ame ⁇ can Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) Chronic Rhinosinusitis Task Force Specifically, CRS alone patients had continuous symptoms of rhinosinusitis as defined by the Task Force report for greater than 12 consecutive weeks, associated with computed tomography of the sinuses revealing isolated or diffuse sinus mucosal thickening and or air fluid level CRSwNP subject was defined by endoscopic exam findings of polyps and post-treatment CT scan confirmation of persistent bilateral and diffuse paranasal sinus mucosal thickening Surgery for CRSwNP patients was only performed if a patient's symptoms and radiographic findings failed to resolve despite at least 6 weeks of treatment with oral antibiotics, topical corticosteroids, decongestants, and/or mucolytic agents in accordance with
- Nasal lavage was collected according to previously desc ⁇ bed methods (Nacle ⁇ o et al (1983) Am Rev Respir Dn, 128,597 602) Lavages were performed with ste ⁇ le saline solution prewarmed to 37° C Bnefly, 5 ml of saline was instilled into each nasal cavity a pipette with the head extended, while the patient holds his/her breath for 10 seconds Then, the patient is asked to tilt his/her head forward to allow the saline to drip into a collection basin The lavage fluid was processed by spinning at 3600 rpm for 15 minutes, ahquoted and frozen in 80 ⁇ C for detection of VEGF, other growth factors, and total protein
- PNEC PNEC Epithelial cells cultured from nasal scrapings were cultured in bronchial epithelial basal medium (Biosource, Cama ⁇ llo, TX) on collagen coated plates as previously descnbed (Kim et al (2005, supra), Heinecke et al (2008) J Allergy Clin Immunol 121 ,1 155 1 160, Kim et al (2000) J Immunol 165, 3384 3392) Cultures, of PNEC routinely were 99-100 % cytokeratin positive staining at the time of harvest PNEC were routinely used for all in vitro studies at first or second passage only For functional studies measunng cell growth and apoptosis, the cells were incubated for varying lengths of time with recombinant VEGF (R&D, Minneapolis, MN, 100 ng/ml, (Conn et al (1990) Proc Natl Acad Su U S A 87, 2628 2632), or antibody that has been previously
- anti-VEGFR2 blocking antibody R&D, 1 ug/ml, (Giuliani et al (2003) Blood 102, 638 645), recombinant EGF (R&D, 50 ng/ml, (Beck et al (2006) J Immunol 177, 3344-3354), or irrelevant isotype control antibody (eBioscience, San Diego, CA)
- Surgical sinonasal tissue was immediately fixed in 4% formaldehyde in phosphate buffered saline (PBS, 4°C, 4 hr) and then rinsed with PBS Antibody to VEGF (R&D), NP-I (Miltenyi), VEGFRl (R&D), VEGFR2 (R&D), phospho-VEGFR2 (Santa Cruz Biotechnology, Santa Cruz, CA), or irrelevant IgG isotype (eBioscience) control was performed as previously descnbed (Kim et al (2005), Heinecke et al (2008), and Kim et al (2000), all supra ) To assure that detection of positive staining was performed in a standardized and uniform manner between tissue samples, staining was routinely performed in sets of tissues using a specimen from each of the two patient groups Each round of staining was exposed to diaminobenzidine for a fixed duration to the standardize time for color development The slides were evaluated with a b ⁇
- ELISA assay for growth factors VEGF, EGF, and TGF ⁇ l from nasal lavages and cell supernatants were measured using ELISA kits from R&D according to manufacturers instructions The minimum detectable concentration of was typically 5 0 pg/ml Assay of each sample was performed in triplicate Data are expressed per ug of total protein that was measured by Bradford assay (Bio Rad, Hercules, CA)
- PNEC growth to culture confluence Two hundred thousand cells/ well were plated onto collagen coated 6 well plates Attainment of culture confluency was assessed under 4OX power phase contrast light microscopy An estimate of confluency was determined by averaging inspection of 5 separate fields 0, 90, 180, 270 degree and center of each well Confluency was defined when a minimum average of 90% has been reached Each sample assay was performed in triplicate and the analysis blinded to the subject group
- Cyquant cell proliferation assay Cell proliferation was assayed using the Cyquant cell proliferation assay (Molecular Probes) Cells were seeded at 5X10 3 cells/well and grown to 50% confluence in 96-well plates in serum-free bronchial EC growth medium (Cambrex), deprived of EGF for 24 hrs before challenge to synchronize cell growth, and subsequently stimulated according to the experimental protocols As per the manufacturer's instructions, at the end of the experiment, the cell supernatants were aspirated and the cells were lifted by trypsimzation Cell lysis was performed by two sequential freeze-thaw cycles Standard curves were executed with each run of the assay according to manufacturers instruction Cells were then incubated for 5 mm at room temperature with Cyquant lysis buffer containing the Cyquant GR fluorescent dye Fluorescence was measured using a Cytofluor 4000 fluorescence reader (Applied Biosystems (Life Technologies) Each experimental condition was assessed in quadruplicates
- siRNA transfection PNEC was grown to 75% confluence and transfected with indicated concentration of target gene NPl (100 nM), negative control, or rhodamine-tagged control siRNA (Qiagen, Valencia, CA) using RNAimax transfection reagent made up in OptiMem buffer (1 1 volume) as directed by vendor (all reagents from Invitrogen) PNEC were then exposed to siRNA/RNAimax in cell culture media without antibiotics (1 3) for 24 hours at 37° C Viability is monitored by light microscopy Transfection efficiency was assessed by measuring average % of rhodamine positive cells per field X 4 sampled fields at 1OX and 4OX magnification using fluorescent microscopy
- a VEGF is elevated in nasal lavages of CRSwNP
- VEGF is overexpressed in vivo and in vitro in CRSwNP
- immunohistochemical staining was performed on sinus tissue surgical samples using monoclonal antibodies against VEGF, and isotype control IgG Sinonasal tissue from CRSwNP (maxillary sinus polyp) and normal control subjects (maxillary or sphenoid sinus) were tested
- the staining intensity of digitized images of epithelial cells was objectively assessed by Image Pro software (Microsoft) and expressed as intensity units per epithelial cell using similar sized sampling areas
- Figure 2A shows that epithelial cell hyperplasia, which is characteristic of CRSwNP, is uniquely present in CRSwNP, and absent from normal control subjects
- Data show that VEGF was detected in representative human sinonasal tissue
- the irrelevant IgG isotype negative control with secondary antibody shown in the inset demonstrates no nonspecific brown staining in
- VEGF Since we found VEGF to be highly expressed on epithelial cells in vivo, we wanted to know if VEGF was detectable on the surface of nasal epithelial cells in vitro VEGF is known to exist on the cell surface residing within an extracellular pool In addition, VEGF is known to exist in a membrane bound form
- Figure 2B (left) display flow cytometric findings using specific monoclonal antibodies to VEGF on nasal epithelial cells taken from infe ⁇ or turbinates which were expanded in cell culture from a normal control subject The anti VEGF antibody used detects all isoforms of VEGF, including membrane bound VEGFl 89
- the results demonstrate fairly unimodal detection of robust levels of cell surface expression of VEGF (94% positive) on PNEC from a normal control subject
- Figure 2B (middle) compares VEGF cell surface expression on PNEC taken from infenor turbinates from control and CRSwNP subjects The data demonstrate that cell surface expression of VEGF from C
- VEGFR2 is known to exhibit robust tyrosine kinase activity and auto and transphosphorylation when activated by VEGF hgand binding
- FIG. 3 A demonstrates that VEGFR2 was detected in human sinonasal tissue from CRSwNP subjects, but barely detectable in normal control subjects (p ⁇ 0 04) Additionally, there was markedly elevated staining of phospho VEGFR2 in polyps of subjects with CRSwNP as compared to specimens from normal control subjects (p ⁇ 0 04) Interestingly, we
- FIG. 6A shows that 48 hour exposure to blocking antibody to NPl resulted in a significant 2 5 fold increase in apoptosis of PNEC from CRSwNP subjects (p ⁇ 0 02) Exposure to blocking antibody to receptor VEGFRl or VEGFR2 resulted in no significant increase in apoptosis of PNEC The combination of blocking antibody to NPl with anti- VEGFRl and/or anti VEGFR2 antibodies resulted in the same level of apoptosis observed with anti-NPl alone (p ⁇ 0 01, p ⁇ 0 02 and p ⁇ 0 05, respectively)
- Figure 6B shows the matching light microscopic appearance of
- G VEGF functions to autoregulate its own expression in PNEC
- FIG. 7 shows that PNEC from CRSwNP produce a remarkable level of constitutive soluble VEGF in the nanomolar range
- Figure 7 shows that exposure of PNEC from CRSwNP subjects to blocking antibodies against VEGFRl or VEGFR2 alone resulted in minimal change (20% and 12% decrease) in soluble VEGF from cell supernatents
- exposure to anti NPl resulted in an enhanced 33% significant inhibition of soluble VEGF expressed by PNEC (p ⁇ 0 05)
- Addition of anti-VEGFRl and/or anti-VEGFR2 to anti-NPl produced no further inhibition of soluble VEGF expression (42%, 36%, and
- nasal epithelial cells from CRSwNP subjects retained their capacity to over express VEGF and maintain their pathological phenotype in vitro when cultured at low passage number (Pl or P2)
- Both soluble and cell surface VEGF is over expressed by PNEC from CRSwNP subjects as compared to normal control PNEC
- these cells show distinctly elevated spontaneous growth rate to culture confluency and proliferation rates as compared to PNEC from normal control subjects, mimicking their in vivo hyperplastic behavior
- bronchial epithelial cells isolated from asthmatic airways maintain can maintain their "abnormal" phenotype when cultured in vitro
- the results from nasal lavages obtained pre- and post- surgery indicate that, on a mass basis, the bulk of soluble VEGF associated with CRSwNP is derived from the polyp tissue
- the nasal epithelial cells taken from CRSwNP subjects were obtained from epithelial cell brushings of the inferior turbinate within the nasal cavity (similar to
- the NPl cell surface receptor acts in the present context via one or more of the following functions that have been previoulsy reported NPl functions as a potent endothelial cell mitogen and regulates vasculature formation NPl is thought to function to increase the binding affinity of VEGF to VEGFR2, by serving as a docking site for hgand binding NPl occurs in a wide va ⁇ ety of tissues, including epithelial cells and tumors
- Our finding that blocking antibodies targeted against NPl virtually mimicked the inhibitory effect of blocking VEGF hgand itself supports our conclusion that activation of NPl is essential for the VEGF-mediated increase in epithelial cell proliferation seen in CRSwNP subjects
- the increase in cell growth observed with CRSwNP epithelium may be explained by a decrease in cell death due to the presence of a survival factor such as autocrine VEGF Since both VEGF and
- VEGF can serve as a biomarker for sinonasal polyposis and have demonstrated a novel role for VEGF as an epithelial cell mitogen and prosurvival factor that functions in a positive feed forward manner
- this function is dependent on NPl , which we report as being constitutively expressed in human upper airway epithelial cells
- NPl which we report as being constitutively expressed in human upper airway epithelial cells
- VEGF-A or a VEGF-A receptor can inhibit epithelial cell mitogenesis in airway cells, and/or that it can be used to treat subjects with chronic inflammatory respiratory disorders
- Inhibitory agents that are specific for one or more of the genes listed in Table 2, or proteins encoded by them, will be tested to confirm the expected result that inhibition of their expression and/or their activity inhibits the proliferation of epithelial cells, e g , airway epithelial cells
- a Rates of apoptosis from PNEC denved from patients will be exposed to inhibitors, and quantitated and compared using flow cytometnc determination of annexin V fluoroscein isothionate (FITC) staining of PNEC grown under standardized conditions in vitro
- FITC fluoroscein isothionate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This invention relates, e.g., to a method for treating a subject having a chronic inflammatory respiratory disorder, comprising administering to the subject an effective amount of an inhibitor of the expression of and/or the activity of VEGF-A and/or VEGFR1 and/or VEGFR2 and/or NP1, or a combination thereof. Also described are screeing assays for agents for treating a subject having a chronic inflammatory respiratory disorder, and kits for performing one of the methods of the invention.
Description
TREATMENT OF CHRONIC INFLAMMATORY RESPIRATORY DISORDERS
This application claims the benefit of the filing date of US provisional applications 61/1 1 1 ,767, filed November 6, 2008, 61/143,488, filed January 9, 2009, and 61/242,158, filed September 14, 2009, all of which are incorporated by reference herein in their entireties
This invention was made with government support under A 1057400 awarded by the National Institutes of Health The government has certain rights in the invention
SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted via EFS-
Web and is hereby incorporated by reference in its entirety Said ASCII copy, created on November 5, 2009, is named 22402820 txt, and is 190,500 bytes in size
BACKGROUND INFORMATION Although chronic rhinosinusitis (CRS) is a widespread disease affecting -15% of the US population, the pathogenesis is poorly understood One of the most severe forms is CRS with hyperplastic sinonasal polyposis (CRSwNP) The presence of hyperplastic polyps in the sinuses is an ominous clinical feature signifying the presence of recalcitrant disease for which there is no known effective lasting treatment Mucosal hyperplasia, a hallmark of the tissue remodeling observed in CRSwNP, results in chronic disease that becomes refractory to either medical or surgical management Despite the significant morbidity of recurrent disease, central mechanisms regarding the pathogenesis of sinonasal polyposis remain poorly understood Histological features of CRSwNP resemble that of asthmatic airways with endstage polyps displaying signs of Th2 inflammation characterized by infiltration with eosinophils, thickening of the basement membrane and hyperplasia of the epithelium and are strikingly reminiscent of the histopathology of severe asthmatic airways Therefore, understanding factors controlling aberrant epithelial cell growth may provide critical insights into therapeutic strategies in the treatment of chronic rhinosinusitis with nasal polyposis, as well as asthma
Despite the fact that epithelial hyperplasia is a key feature of sinonasal polyps, there is a surprising paucity of literature on studies of growth factors in the pathogenesis of epithelial hyperplasia in sinonasal polyps Growth factors implicated in remodeling of asthmatic airways such as transforming growth factor β (TGFβ) and fibroblast growth factor (FGF) were found to be increased in nasal polyp tissue. Messenger RNA for TGFβ l and FGF are increased in tissue homogenates of polyps Imunohistochemical analysis localized TGFβl to the extracellular
matrix and stroma of nasal polyps, where eosinophils reside There have been many studies of other selected growth factors in nasal polyposis, such as insulin like growth factor (IGF), FGF, PDGF, and TGF beta However, the effects of TGF and FGF on sinus tissue remodeling have not been established Epidermal growth factor (EGF) is thought to play a key role in epithelial proliferation, growth and repair in asthma EGF receptor over expression in bronchial epithelial cells has been found to correlate with asthma severity and steroid refractoπness However the role of EGF in development of sinonasal polyps has not been explored
VEGF (vascular endothelial cell growth factor) as an endothelial cell mitogen has been implicated in the development of nasal polyps lmmunohistochemical analysis of nasal polyps from children showed increased VEGF staining within the vascular endothelium and increased mean blood vessel count both of which correlated with size of nasal polyps Others have also shown that enhanced VEGF and its receptor expression were localized to the endothelium, the basement membranes, penvascular spaces, and epithelium of polyps These studies indicate that the epithelium is a significant, but not necessarily the sole, source of VEGF in polyp tissue, but they do not show if the VEGF found in the epithelium was produced in those cells or whether it was actually generated by endothelial cells Moreover, there have been no investigations to date on the role of VEGF as an epithelial mitogen in sinus disease
DESCRIPTION OF THE DRAWINGS Figure 1 shows a companson of soluble growth factors in nasal lavages of untreated CRSwNP, CRSwNP patients at 1 month post operatively, CRS alone, and normal control subjects VEGF and EGF in nasal lavages were assayed according to manufacturer's instruction (antibodies and kits from R&D Systems) The lower limit of detection was 5 pg/ml Values represent the mean +/ SEM '■ p<0 001 vs Control, CRS alone, or CRSwNP post op subjects by Kruskal Walhs Test Human subjects data is shown in Table 1
Figure 2 shows that VEGF is over expressed by epithelial cells in sinonasal tissue Fig. 2A shows surgical sinonasal tissue from CRSwNP (πght, n=5) and normal control sinus mucosa (left, n=5) that were immediately placed in 4% paraformaldehyde and processed for lmmunohistochemical staining of VEGF as described in Methods Score shown in ( ) is the brown colored staining intensity expressed as mean intensity x 103 /cell +/ SEM determined using Image Pro software (Media Cybernetics, Silver Spreing, MD) Each inset represents the matching IgG control Data are representative of n=5 subjects in each group and are shown at 1OX magnification !p<0 012 by Kruskal Walhs Test Fig. 2B shows flow cytometric analysis of
cell surface VEGF on cultured PNEC (primary nasal epithelial cells) from normal control and CRSwNP subjects Fig. 2C shows soluble VEGF isoforms 165 and 121 in cell supernatents of PNEC, measured by ELISA according to manufacturers instructions (R&D) Lower limit of detection was 5 pg/ml xp<0 05 and *xp<0 02 vs Control subject by Kruskal Wallis Test
Figure 3 shows that receptors for VEGF are abundantly expressed by epithelial cells in sinonasal tissue Fig. 3A shows expression of VEGFR2, phospho VEG FR2, and NPl by epithelial cells in sinonasal tissue Surgical sinonasal tissue from CRSwNP (n=5) and normal control sinus mucosa (n=5) were immediately placed in 4% paraformaldehyde and processed for immunohistochemical staining of VEGFR2, phospho VEGFR2 and NPl , as described in Methods Score shown in ( ) is the brown colored staining intensity expressed as mean xlO3 intensity/cell +/- SEM determined using Image Pro software (Macintosh) Data are shown at 1OX magnification. Figure 3B shows flow cytometric analysis of cell surface NPl expression on PNEC from normal control and CRSwNP subjects *p<0 04 vs control by Kruskal Wallis Test, n=6 for each group
Figure 4 shows that primary nasal epithelial cells (PNEC) from CRSwNP subjects display faster growth rates in vitro Fig. 4A shows a compaπson of time to confluence of cultures of PNEC from normal control and CRSwNP subjects PNEC from normal control and CRSwNP subjects were cultured as described in Methods. Results are expressed as # days to confluency of culture from day of seeding into 6 well plates and assessed in triplicate Fig. 4B shows a compaπson of cell proliferation rates of PNEC from normal control and CRSwNP subjects Cell number was determined by normalization of DNA content to a standard curve using Cyquant cell proliferation assay as described in Methods Each circle indicates an experiment from a single donor Bars represent the mean *p<0 008 or **p<0 005 vs control group by Kruskal Wallis Test
Figure 5 shows that sinonasal epithelial cell growth is VEGF dependent Fig. 5A shows the effects of anti-VEGF antibody and recombinant EGF exposure on growth rates of PNEC from CRSwNP subjects Fig. 5B shows the effects of anti-NPl , anti- VEGFRl (vascular endothelial cell growth factor 1), and anti-VEGFR2 (vascular endothelial cell growth factor 2) antibody exposures on growth rates of PNEC from CRSwNP subjects Fig. 5C shows the effects of combination of anti-NPl , anti-VEGFRl , and anti-VEGFR2 antibody exposures on growth rates of PNEC from CRSwNP subjects PNEC from CRSwNP subjects were seeded at 5000
cells/well of a 96 well plate and exposed to designated blocking antibodies, recombinant EGF (R&D Systems) or IgG control antibody as described in Methods Cell number was determined after normalization of DNA fluorescence to a standard curve using Cyquant cell proliferation assay as described in Methods Each curve represents the mean of 5 expenments, each from an individual CRSwNP donor Each condition and time point was measured in quadruplicate SEM ranged between 12-27% of the mean ^p<0 05, or *"p<0 02, vs Control condition at 96 hours by ANOVA and post hoc Bonferroni
Figure 6 shows that functional blocking of NPl results in apoptosis PNEC from CRSwNP subjects (n=5) were grown to 90% confluence and incubated for 48 h with blocking antibodies to NPl (1 ug/ml), VEGFRl (Rl, 10 ug/ml), VEGFR2 (R2, 1 ug/ml), IgG control (1 ug/ml), or media control and processed for flow cytometπc analysis of annexin V FlTC staining (R&D) Results in the Fig. 6A are expressed as mean +/-SEM of % cells staining positive for annexin Fig. 6B shows light microscopic views of PNEC under 2OX power White arrows point to cell membrane blebs *p<0 001, "p<0 02, or xκ>:p<0 05 vs Control condition by ANOVA and post hoc Bonferroni Test
Figure 7 shows that functional blocking of NPl results in the inhibition of autocπne VEGF expression by PNEC PNEC from CRSwNP subjects (n=3) were incubated for 48 h with blocking antibodies to NPl (1 ug/ml), VEGFRl (Rl , 10 ug/ml), VEGFR2 (R2, 1 ug/ml), IgG control (1 ug/ml) or media control Then cell supernatants were harvested and assayed for VEGF by ELISA as described in Methods xp<0 05 vs Control condition by ANOVA and post hoc Bonferroni Test
Figure 8 shows that siRNA knockdown of NPl results in inhibition of autocπne VEGF expression by PNEC PNEC from CRSwNP subjects were transfected with three non overlapping siRNA sequences against NPl or scrambled negative control for 24 hours as descnbed in Methods Untransfected media control was also used (Control) Gif. 8A shows flow cytometric analysis of cell surface VEGF Data represent the mean fluorescence intensity +/- SEM of n=4 expenments *p<0 05 vs media control by ANOVA with post hoc Bonferroni Test Fig. 8B shows fluorescent and matching light micrographs of PNEC transfected with rhodamine-tagged control siRNA Fig. 8C shows realtime PCR analysis of NPl mRNA Panel Fig. 8D shows flow cytometπc analysis of cell surface NPl Data represent the mean +/- SEM of n= 3 experiments Analysis by ANOVA with post hoc Bonferroni Test resulted in "*p<002
for all 3 siRNA NPl vs media control or negative control siRNA (siControl) κ-<xp<0 05 for siRNA 1 or siRNA 2 for NPl vs media control +p<0 05 for siRNA2 for NPl vs negative control siRNA
DESCRIPTION OF THE INVENTION
The present inventors demonstrate herein that VEGF is a central pathway by which airway epithelial cell growth is regulated To demonstrate this, they used the following in vivo and in vitro human experimental models (1) nasal lavage aspirates, (2) surgical sinonasal tissue, and (3) cultured primary nasal airway epithelial cells The identification of VEGF-A, the VEGF-A receptors, VEGF receptor 1 (VEGFRl ) and VEGF receptor 2 (VEGFR2), and VEGF- A co-receptor, neuropilin-1 (NPl), as targets for the treatment of chronic inflammatory respiratory disorders provides the basis for new types of treatments for this class of disorders
One aspect of the invention is a method for inhibiting the proliferation of epithelial cells, compπsing contacting the cells with an effective amount of an inhibitor of the expression of and/or of the activity of VEGF A, and/or VEGFRl , and/or VEGFR2, and/or NPl Furthermore, other, related members of the VEGF-A family, such as the VEGF isoforms (splice variants), VEGF 165, VEGF 121, or VEGF 189, or the homologs, VEGF-B, VEGF-C, VEGF-D, or P/GF (placental growth factor), can serve as targets In addition, it is expected that VEGFR3 and NP2, which are known to interact with some of the molecules noted above, can also serve as targets Furthermore, NPl is known to engage other ligands or co-receptors, which are also expected to be involved in the proliferation of epithelial cells and which can thus be inhibited by a method of the invention These additional proteins include, e g , Plexin Al , A2, A3 or A4, integπn beta- 1 , TGF beta-1, FGF2, FGF4, HGF and galectin-1
The epithelial cells whose growth is inhibited by a method of the invention can be in vitro, in cell culture These cells can be primary cell cultures, or cells from an established cell line (e g , BEAS2B, A549 or 16HBE cells, all of which are available from the American Type Culture Collection, Manassas, VA) Alternatively, the epithelial cells whose growth (hyperplasia) is inhibited can be in vivo, in a subject (e.g , a subject having a chronic inflammatory respiratory disorder) One embodiment of this latter method is a method for treating a subject having a chronic inflammatory respiratory disorder, or for preventing the development of such a disorder, compπsing administering to the subject an effective amount of an inhibitor of the expression of, and/or of the activity of, VEGF-A, and/or VEGFRl, and/or VEGFR2, and/or NPl , and/or one of the other hgands, receptors, or co-receptors noted above,
and/or combinations thereof Such inhibitors* or combinations of inhibitors are sometimes referred to herein as "inhibitors of the invention."
Among the types of chronic inflammatory respiratory disorder that can be treated by a method of the invention are, e.g , chronic rhinosinusitis with nasal polyposis (CRSwNP), chronic rhinosinusitis without nasal polyposis, asthma (in adults or a pediatric population), chronic obstructive pulmonary disease (COPD), allergic and/or nonallergic rhinitis, or allergic bronchopulmonary aspergillosis, or cystic fibrosis All of these disorders are airway inflammatory disorders, for which dysfunctional airway epithelial cells are central A method of the invention targets these disturbed epithelial cells At least some of these condtions, including asthma, exhibit a histological appearance and behavior (recurrences and exacerbations) that are identical to that of CRSwNP It is expected that cystic fibrosis, another airway inflammatory disorder, can also be treated by a method of the invention
An inhibitor of the invention can be, e g , an antibody or antibody fragment, an inhibitory RNA (siRNA, microRNA, etc), a small molecule, a peptide, or the like In one embodiment of the invention, the inhibitor comprises an antibody (e g , a blocking antibody) against VEGF, NP-I, VEGFRl , VEGFR2, or combinations thereof In other embodiments, the inhibitor comprises a blocking antibody against other combinations of the proteins noted above For example, the inhibitor can comprise a blocking antibody against
1) VEGF A in combination with one or more of VEGFRl, VEGFR2 and VEGFR3, (2) NPl in combination with one of more of VEGFRl , VEGFR2, VEGFR3, integrin beta-1 , TGF beta-1, FGF2, FGF4, hepatocyte growth factor/scatter factor, and galectin-1,
(3) NP2 in combination with one or more of VEGFRl , VEGFR2, VEGFR3, integπn beta-1, TGF beta-1, FGF2, FGF4, hepatocyte growth factor/scatter factor, and galectin-1 ,
(4) NPl in combination with VEGF-A, (5) NP2 in combination with VEGF-A, or
(6) VEGF-A, (NPl or NP2), and (VEGFRl or VEGFR2),
(7) NPl , or
(8) VEGF-A
As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise For example, "an" anti-VEGF blocking antibody, as used above, means one or more anti-VEGF blocking antibodies, which can be the same or different
In another embodiment, the inhibitor is an RNA aptamer, such as pegaptamb, a partial or full-length antibody, such as ranibizumab or bevacizumab, a VEGF receptor decoy, such as VEGF Trap (see, e g , USP 7,541 ,172), small interfering RNA-based therapies, such as a
microRNA or an siRNA, including the siRNAs described herein, microRNAs, bevasiranib, or AGN21 1745, a tyrosine kinase inhibitor, such as vatalamb, pazopanib, TG 100801, TGlOl 095, AG013958 or AL39324, a small molecule, or a blocking peptide For example, one can use a blocking peptide against the VEGF receptors NPl and/or VEGFR2, such as those descπbed in Barr et al (2005) Br J Cancer 92, 328-333
An inhibitor of the invention can be administered by, e g , systemic intravenous (IV) or by an intranasal route
Another aspect of the invention is a method for screening for agents that can be used to treat a chronic inflammatory respiratory disorder In one embodiment of the invention, the method comprises screening putative inhibitory agents for their ability to inhibit the growth of suitable epithelial cells in culture (such as cultured primary nasal epithelial cells (PNEC), primary bronchial epithelial cells (PBEC), or suitable established cell lines, such as BEAS2B, A549 or 16HBE cells) Cell growth can be assayed by any of a vaπety of methods, including, e g , using Cyqyant dye or BUdR In another embodiment, putative inhibitory agents are screened for their ability to induce apoptosis of such epithelial cells Apoptosis can be measured by any of a variety of methods, including, e g , flow cytometric analysis of annexin In another embodiment, putative inhibitory agents are screened for their ability to inhibit autocrine VEGF in the supernatant of such cells, e g using an ELISA assay In another embodiment, putative inhibitory agents are tested for their ability to inhibit cell growth or cell survival of whole intact diseased sinus polyps ex vivo, using quantitative immunohistochemical PCNA staining or TUNEL staining, respectively
Another aspect of the invention is a kit for treating a subject having a chronic inflammatory respiratory disorder, or for preventing the development of such a condition, compπsing a) an effective amount of an inhibitor of the expression of, and/or the activity of, VEGF
A, and/or VEGFRl , and/or VEGFR2, and/or NPl (or other combinations of proteins as discussed above), and b) reagents or devices for introducing the inhibitor into the airway of the subject, e g , by an intranasal route For example, the kit can comprise applicators that are suitable for administering the agent as a nasal spray or as a topical lavage (nasal wash solution, for bathing the sinuses and nose with the agent)
The Examples herein are directed primarily to VEGF A (which is sometimes referred to as VEGF) However, it will be clear to a skilled worker that a variety of other targets are implicated by the expeπments presented herein, including VEGF C, VEGF-D or P/GF
(placental growth factor) There is a great deal of redundancy in the VEGF gene family and in the VEGF receptor gene families For example, VEGFR 1 and VEGFR2 are each mitogens for endothelial cells, but in different organ systems, VEGFRl is mostly involed in promoting lymphangiogenesis, while VEGFR2 is mostly involved in vascular angiogenesis There is also some overlap in the activities of these receptors It will be understood by a skilled worker that references to "VEGF A" or 'VEGF receptors" herein include a variety of other, related targets Some of these targets are listed in Table 2
A "VEGF-A receptor," as used herein, is a receptor which VEGF A binds to and subsequently activates Such receptors include, e g , NP-I , VEGFRl (FIt-I) and VEGFR2 (FIk- 1/KDR)
Sequences of some of the targets that can be used in a method of the invention, and their GenBank accession numbers, are provided in the Sequence Listing attached to this application These include the genes listed in Table 1 The GenBank numbers refer to the nucleic acid sequences The sequences of proteins encoding by these nucleic acids will be evident to a skilled worker Table 2
SEQ ID
Name of Target Gene Acronym Gene Bank# NO:
VEGF-A N MJ)01025366 1 13
VEGF B NM_003377 3 14
VEGF C NM_005429 2 15
VEGF D NM_004469 2 16
Placental Growth Factor PIGF NM_002632 4 17
Neuropιlιn-1 NPl NM_003873.5 27
Neuropιlιn-2 NP2 NM_201266.1 28
VEGF Receptor 1 VEGFRl NM_002019.4 29
VEGF Receptor 2 VEG FR2 NM_002253.2 30
VEGF Receptor 3 VEG FR3 NM_002020.4 31
Semaphoπn 3A Sema 3A NM_006080.2 18
Semaphoπn 3C Sema 3C NM_006379.2 19
Semaphoπn 3F Sema3F NM _004186.3 20 integrin beta-1 integrin beta-1 NM _002211.3 21 transforming growth factor 22 beta-1 TGF beta 1 NM _000660.4 fibroblast growth factor 2 FG F2 NM _002006.4 23 fibroblast growth factor 4 FG F4 NM _002007.2 24 hepatocyte growth factor/scatter 25 factor HGF NM 000601.4 galectιn-1 galectιn-1 NM_001009287.1 26 plexin A1 PLXNA1 NM_032242.3 32 plexin A2 PLXNA2 NM_025179.3 33 plexin A3 PLXNA3 NM_017514.3 34 plexin A4 PLXNA4 NM 020911.1 35
A "subject," as used herein, can refer to any animal which is subject to a chronic inflammatory respiratory disorder, e g , a mammal, such as an experimental animal, a farm animal, pet, or the like In some embodiments, the animal is a primate, preferably a human An "effective amount" of an inhibitor of the invention is an amount that is effective to elicit a measurable amount of biological activity, e g a measurable amount of suppression or inhibition of VEGF-A mediated proliferation of epithelial cells, or inhibition of a chronic inflammatory respiratory disorder Perferably, an effective amount of an inhibitor of the invention does not elicit substantial amounts of undesirable (e g , toxic) effects The suppression or inhibition can occur prophylactically (e g , preventively, to inhibit the development of the disorder), or in a subject who already has the condition For example, treatment with an inhibitor of the invention can ameliorate one or more symptoms of the condition
Any of a vaπety of types of agents can be used to inhibit the expression or activity of, e g , VEGF-A or a VEGF-A receptor in a method of the invention An "inhibitor" of expression or activity is an agent that reduces the expression or activity by a detectable amount
Methods for making and using inhibitors of the invention are conventional and well- known in the art Guidance in performing some of the methods of the invention is provided, for example, in Sambrook et al , Molecular Cloning, A Laboratory Manual (volumes I-III), Cold Spπng Harbor Laboratory Press, USA or Harlowe and Lane, Antibodies a Laboratory Manual 1988 and 1998, Cold Spring Harbor Laboratory Press, USA These and other references cited
herein which provide guidance for performing methods related to the present invention are incorporated by reference herein in their entirety
In one embodiment of the invention, the inhibitory agent inhibits the expression of VEGF-A or a VEGF A receptor The term "expression" of a gene, as used herein, refers to any aspect of the process by which information in a gene is converted to a functional molecule, e g , any aspect of transcription or translation of the gene For example, "expression" can refer to transcription, post-transcπptional processing, translation, or post-translational processing Examples of inhibitors of expression include an antisense nucleic acid, a nbozyme, a microRNA, or a small interfering RNA (siRNA), which is specific for a nucleic acid encoding VEGF-A or a VEGF-A receptor By "specific for" VEGF A or a VVEGF-A receptor is meant that the agent preferentially inhibits the expression of VEGF-A or a VEGF-A receptor, compared to the expression of other proteins An agent that is specific for a particular sequence can bind preferentially to that sequence, under conventional conditions of high stπngency In one embodiment, the inhibitor is an antisense nucleic acid which comprises a single-stranded polynucleotide that is specific for a sequence encoding VEGF-A or a VEGF A receptor, or a portion of one of those sequences. The nucleic acid sequences encoding VEGF-A and its receptors are well-known in the art For example, one can access sequences encoding these proteins in publically available databases, such as the GenBank database operated by the NCBI The GenBank accession numbers and sequences for some suitable targets are presented in Table 2 and in the Sequence Listing herein
Each of these accession numbers, in conjunction with the names and unique gene symbols of the genes, is adequate to unambiguously identify these genes Furthermore, the sequence (and the corresponding SEQ ID number) of a nucleic acid corresponding to each marker (e g , a transcπbed RNA, a cDNA or a genomic sequence) is also provided The sequences were obtained from the GenBank database (at the world wide web site ncbi nlm nih gov/Genbank), and the GenBank Accession Numbers (e g , NM numbers) are provided in Table 2 and in the Sequence Listing Note that the sequences that are presented herein are correct as of the day of filing of this application However, in GenBank, sequences are periodically updated by the NCBI to correct errors As the sequences are curated, and new sequences replace previous sequences that contained errors, the replacement is descnbed in the COMMENT section of the GenBank entry Sequences that are subsequently corrected are encompassed by the present application At any given time, only a single sequence is associated with each GenBank Accession Number There is no indefiniteness, variability or uncertainty as
to the sequence that is associated with any particular accession number at the time this application was filed The sequences, and the GenBank accession numbers with which they are associated, are hereby incorporated by reference
A skilled worker would be able to design, make and use suitable antisense molecules, based on these or other sequences, without undue expeπmentation The antisense nucleic acid may be, e g , an oligonucleotide, or a nucleic acid comprising an antisense sequence that is operably linked to an expression control sequence, and that is expressed in the cell
The use of antisense nucleic acids to downregulate the expression of a particular protein in a cell is well known in the art See, e g , Weintraub et al (1986) Reviews Trends in Genetics 1(1), Askan et al (1996) JV Eng J Med 334, 316-318, Bennett et al (1995) Circulation 92, 1981 1993, Mercola et al (1995) Cancer Gene Ther 2, 47 59, Rossi et al (1995) Br Med Bull 51 217 225, or Wagner, R W (1994) Nature 372, 333-335 An antisense nucleic acid molecule may comprise a nucleotide sequence that is complementary to the coding strand of another nucleic acid molecule (e g , an mRNA sequence), or to a portion thereof, and accordingly is capable of hydrogen bonding to the coding strand of the other nucleic acid molecule Alternatively, antisense sequences can be complementary to a sequence found in the 5' or 3' untranslated region of the mRNA or a region bπdging the coding region and an untranslated region (<? g , at the junction of the 51 untranslated region and the coding region) The antisense nucleic acid can be complementary in sequence to a regulatory region of the gene encoding the mRNA, for instance a transcription initiation sequence or regulatory element, or a splice site In one embodiment, an antisense nucleic acid is designed so as to be complementary to a region preceding or spanning the initiation codon on the coding strand or in the 3' untranslated region of an mRNA An antisense nucleic acid for inhibiting the expression of a protein of interest in a cell can be designed based upon the nucleotide sequence encoding the protein or upon sequences regulating its transcription or translation, constructed according to the rules of Watson and Crick base pairing
For guidance in constructing antisense molecules that are complementary to a region of a gene involved in transcription (thereby blocking transcription and/or the production of isoforms, such as splice variants), see, e g, Lee et al (1979) Nucl Acids Res 6, 3073, Cooney et al (1988) Science 24J_, 456, and Dervan et al ( 1991) Science 25_L 1360 For further guidance on administering and designing antisense, see, e g , U S Pat Nos 6,200,960, 6,200,807, 6, 197,584, 6,190,869, 6,190,661 , 6, 187,587, 6, 168,950, 6,153,595, 6,150,162, 6, 133,246, 6, 1 17,847, 6,096,722, 6,087,343, 6,040,296, 6,005,095, 5,998,383, 5,994,230, 5,891 ,725, 5,885,970, and 5,840,708
An antisense nucleic acid can exist in a vanety of different forms For example, it can be DNA, RNA, PNA or LNA, or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double stranded The nucleic acid can be modified at the base moiety, sugar moiety, or phosphate backbone, using conventional procedures and modifications Modifications of the bases include, e g , methylated versions of purines or pynmidines Modifications may include other appending groups such as peptides, or agents facilitating transport across the cell membrane (see, e g Letsinger et al , 1989, Proc Natl Acad Sci USA 84 684 652, PCT Publication WO 88/09810 (1988), hybπdization-tπggered cleavage agents {e g Krol et al , 1988, BwTechniques 6 958 976) or intercalating agents {e g , Zon, 1988, Pharm Res 5 539 549)
Antisense nucleic acids (e g , oligonucleotides) can be constructed using chemical synthesis procedures known in the art Such an antisense nucleic acid can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e g phosphorothioate deπvatives and acπdine substituted nucleotides can be used To inhibit expression of VEGF A or a VEGF A receptor in cells in culture, such antisense nucleic acids can be added to cells in culture media Typically, synthetic oligonucleotides are added to a final concentration of about 1OnM to about 100OnM, preferably about 50 nM to about 200 nM {e g , about 200 μg ohgonucleotide/ml)
Alternatively, an antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense onentation (ι e , nucleic acid transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest) Expression control sequences (e g , regulatory sequences) operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the expression of the antisense RNA molecule in a cell of interest For instance, promoters and/or enhancers or other regulatory sequences can be chosen which direct constitutive, tissue specific or inducible expression of antisense RNA Inducible expression of antisense RNA, regulated by an inducible eukaryotic regulatory system, such as the Tet system {e g , as described in Gossen et al (1992) Proc Natl Acad Sci USA 89, 5547 5551 , Gossen et al (1995) Science 268, 1766 1769, PCT Publication No WO 94/29442, and PCT Publication No WO 96/01313) can be used The antisense expression vector can be in the form of, for example, a recombinant plasmid, phagemid or attenuated virus The antisense expression vector can be introduced into cells using standard techniques well known in the art An antisense
molecule of the invention can be complementary to any portion of a VEGF-A or VEGF-A receptor encoding or regulatory sequence
In another embodiment, an inhibitory agent of the invention is a nbozyme Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a smgle- stranded nucleic acid, such as an mRNA, to which they have a complementary region For reviews on πbozymes see e g , Ohkawa et al ( 1995) J Biochem 1 18, 251-258, Sigurdsson et al (1995) Trends Bwtechnol Ϊ 3_, 286-289, Rossi, J J (1995) Trend:, Biotethnol Vi, 301-306, Kiehntopf et al (1995) J MoI Med 73, 65 71 ) A nbozyme having specificity for an mRNA of interest can be designed based upon the nucleotide sequence of , e g , the corresponding cDNA For example, a deπvative of a Tetrahymena L- 19 IVS RNA can be constructed in which the base sequence of the active site is complementary to the base sequence to be cleaved in a VEGF-A or VEGF-A receptor mRNA See for example U S Pat Nos 4,987,071 and 5, 1 16,742, both by Cech et al Alternatively, human VEGR A or a VEGF-A receptor mRNA can be used to select a catalytic RNA having a specific nbonuclease activity from a pool of RNA molecules See for example Bartel et al (1993) Science 261, 141 1-1418
In another embodiment, the inhibitor is an siNA (a double-stranded nucleic acid, preferably an RNA, which is sometimes referred to as a small or short, interfering or inhibitory, nucleic acid When the nucleic acid is an RNA, the molecule is sometimes referred to as an siRNA), used in a method of RNA interference to interfere with protein expression, and directed to VEGF-A, NP-I , VEGFRl, VEGFR2, or combinations thereof Based on the well known sequences of nucleic acids encoding these proteins, a skilled worker would be able to design, make and use any of a vanety of suitable siNAs (e g , siRNAs), based on these sequences, without undue experimentation For example, the siRNA can comprise a single-stranded polynucleotide represented by one of the following sequences that are descπbed in the Examples herein CCACAUUUCACAAGAAGAUUGUGCA (SEQ ID NO 1), UGCACAAUCUUCUUGUGAAAUGUGG (SEQ ID NO 2), GCCAGGAUA CGAAGGUGAAGGAGAA (SEQ ID NO 3), UUCUCCUUCACCUUCGUAUCCUGGC (SEQ ID NO 4), UCUGUCGCUACGACCGGCUAGAAAU (SEQ ID NO 5), or AUUUCUA GCCGGUCGUAGCGACAGA (SEQ ID NO 6), or an active vaπant thereof, or a complement of the sequence or of the active variant
An "active" fragment or vaπant, as used herein, refers to a fragment or vanant of one of the preceding nucleic acids (SEQ ID NOs 1-6) which retains at least one activity of that nucleic acid (e g , the ability to suppress the expression of VEGF-A or a VEGF-A receptor, and/or to inhibit a chronic inflammatory respiratory disorder) For example, nucleic acids comprising
small substitutions, additions, deletions, etc, are tolerated provided they retain such an activity, Nucleic acids that exhibit at least about 90% (e g , at least about 95%, or at least about 98%) sequence identity to a nucleic acid of interest, or to an active fragment thereof, are also included Methods for determining if a nucleic acid exhibits a particular percent identity to a nucleic acid are conventional A "complement" of a nucleic acid, as used herein, refers to a complete complement
As used herein, the term siNA is meant to be equivalent to other terms used to describe nucleic acid molecules that are capable of mediating sequence specific RNAi (RNA interference), for example short (or small) interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), short hairpin RNA (shRNA), short interfenng oligonucleotide, short interfenng nucleic acid, short interfenng modified oligonucleotide, chemically-modified siRNA, post-transcnptional gene silencing RNA (ptgsRNA), translational silencing, and others Long double-stranded interfenng RNAs, such as miRNAs, appear to tolerate mismatches more readily than do short double-stranded RNAs In addition, as used herein, the term RNAi is meant to be equivalent to other terms used to descnbe sequence-specific RNA interference, such as post-transcnptional gene silencing, or epigenetics For example, siNA molecules of the invention can be used to epigenetically silence genes at both the post-transcnptional level or the pre-transcnptional level In a non-limiting example, epigenetic regulation of gene expression by siNA molecules of the invention can result from siNA mediated modification of chromatin structure to alter gene expression (see, for example, Allshire (2002) Science 297, 1818-1819, Volpe et al (2002) Science 297, 1833-1837, Jenuwein (2002) Science 297, 2215-2218, and Hall et al. (2002) Science 297, 2232-2237.)
An siNA can be designed to target any region of the coding or non-coding sequence of a gene. An siNA is a double-stranded polynucleotide molecule comprising self-complementary sense and antisense regions, wherein the antisense region comprises nucleotide sequence that is complementary to nucleotide sequence in a target nucleic acid molecule or a portion thereof and the sense region has a nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof The siNA can be assembled from two separate oligonucleotides, where one strand is the sense strand and the other is the antisense strand, wherein the antisense and sense strands are self-complementary The siNA can be assembled from a single oligonucleotide, where the self-complementary sense and antisense regions of the siNA are linked by means of a nucleic acid based or non-nucleic acid-based hnker(s) The siNA can be a polynucleotide with a hairpin secondary structure, having self-complementary sense and antisense regions The siNA can be a circular single-stranded polynucleotide having two or more loop structures and a stem
comprising self-complementary sense and antisense regions, wherein the circular polynucleotide can be processed either in vivo or in vitro to generate an active siNA molecule capable of mediating RNAi The siNA can also compπse a single-stranded polynucleotide having nucleotide sequence complementary to nucleotide sequence in a target nucleic acid molecule or a portion thereof (or can be an siNA molecule that does not require the presence within the siNA molecule of nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof), wherein the single stranded polynucleotide can further compπse a terminal phosphate group, such as a 5'-phosphate (see for example Martinez et al (2002) Cell 1 10, 563-574 and Schwarz et al (2002) Molecular Cell K), 537-568), or 5',3'-diphosphate In certain embodiments, the siNA molecule of the invention compnses separate sense and antisense sequences or regions, wherein the sense and antisense regions are covalently linked by nucleotide or non-nucleotide linkers molecules as is known in the art, or are alternately non covalently linked by ionic interactions, hydrogen bonding, van der waals interactions, hydrophobic interactions, and/or stacking interactions As used herein, siNA molecules need not be limited to those molecules containing only
RNA, but further encompasses chemically-modified nucleotides and non-nucleotides In certain embodiments, the short interfering nucleic acid molecules of the invention lack 2'-hydroxy (2'- OH) containing nucleotides In certain embodiments, short interfering nucleic acids do not require the presence of nucleotides having a 2'-hydroxy group for mediating RNAi and as such, short interfering nucleic acid molecules of the invention optionally do not include any ribonucleotides (e g , nucleotides having a 2'-OH group) Such siNA molecules that do not require the presence of ribonucleotides within the siNA molecule to support RNAi can however have an attached linker or linkers or other attached or associated groups, moieties, or chains containing one or more nucleotides with 2'-OH groups Optionally, siNA molecules can compπse ribonucleotides at about 5, 10, 20, 30, 40, or 50% of the nucleotide positions The modified short interfering nucleic acid molecules of the invention can also be referred to as short interfeπng modified oligonucleotides "siMON " Other chemical modifications, e g , as descπbed in PCT/US03/05346 and PCT/US03/05028, can be applied to any siNA sequence of the invention Preferably an RNA interference molecule has a 2 nucleotide 3' overhang If the RNA interference molecule is expressed in a cell from a construct, for example from a hairpin molecule or from an inverted repeat of the desired VEGF-A or VEGF-A receptor sequence, then the endogenous cellular machinery will create the overhangs
Considerations to be taken into account when designing an RNAi molecule include, e.g., the sequence to be targeted, secondary structure of the RNA target and binding of RNA binding proteins. Methods of optimizing siRNA sequences will be evident to the skilled worker.
Typical methods are described, e.g., in Vickers et al. (2003) J Biol Chem 278, 7108-71 18 and Yang et al. (2003) Proc Natl Acad Sci USA 99, 9942-9947.
Methods of making siNAs (e.g., siRNAs) are conventional and will be evident to the skilled worker. In vitro methods include, e.g., processing the VEGF-A or VEGF-A receptor ribopolynucleotide sequence in a cell-free system (e.g., digesting long double-stranded RNAs with RNAse III or Dicer), transcribing recombinant double-stranded VEGF-A or VEGF-A receptor DNA in vitro, and chemical synthesis of nucleotide sequences homologous to a VEGF- A or VEGF-A receptor sequence. See, e.g., Tuschl et al. (1999) Genes & Dev. B., 3191 -3197. In vivo methods include, e.g., (1) transfecting DNA vectors into a cell such that a substrate is converted into siRNA in vivo [see, e.g., Kawasaki et al. (2003) Nucleic Acids Res 3_1_, 700-707; Miyagishi et al. (2003) Nature Biotechnol 20, 497-500; Lee et al. (2002) Nature Biotechnol 20, 500-505, Brummelkamp et al. (2002) Science 296, 550-553; McManus et al. (2002) RNA 8, 842-850; Paddison et al. (2002a) Gene Dev .16, 948-958; Paddison et al. (2002b) Proc Natl Acad Sci USA 99, 1443-1448); Paul et al. (2002) Nature Biotechnol 20, 505-508; Sui et al. (2002) Proc Natl Acad Sci USA 99, 5515-5520; Yu et al. (2002) Proc Natl Acad Sci USA 99, 6047-6052J; (2) expressing short hairpin RNAs from plasmid systems using RNA polymerase III (pol III) promoters [.see, e.g., Kawasaki et al. (2003) (supra), Miyagishi et al. (2003) (supra), Lee et al. (2002) (supra), Brummelkamp et al. (2002) (supra), McManus et al. (2002) (supra), Paddison et al. (2002a) (supra), Paddison et al. (2002b) (supra), Paul et al. (2002) (supra), Sui et al. (2002) (supra) and Yu et al. (2002) (supra)]; and/or (3) expressing short RNA from tandem promoters Lsee, e.g., Miyagishi et al. (2003) (supra) and Lee et al. (2002) (supra)]. When synthesized in vitro, a typical 0.2 micromolar-scale RNA synthesis provides about
1 milligram of siRNA, which is sufficient for about 1000 transfection experiments using a 24- well tissue culture plate format. In general, to inhibit VEGF-A or VEGF-A receptor expression in cells in culture, one or more siRNAs can be added to cells in culture media, typically to a final concentration of about 50-200μg, preferably about 50 μg siRNA/ml. Any of a variety of conventional methods can be used to introduce siNAs into cells, including transfection, electroporation, or other methods known in the art. See, e.g., Hannon (2002) Nature 418, 244-251 ; Bernstein et al. (2002) RNA 7, 1509-1521 ; Hutvagner et al, Curr. Opin. Genetics & Development YL, 225-232; Brummelkamp (2002) Science 296, 550-553; Lee et al. (2002) Nature Biotechnol 20, 500-505; Miyagishi et al. (2002) Nature Biotechnol. 20,
497-500, Paddison et al (2002) Genes & Dev .16, 948-958, Paul et al (2002) Nature Bwtechnol 20, 505-508, Sm et al (2002) Proc Natl Acad Sci USA 99, 5515 5520, and Yu et al (2002) Proc Natl Acad Sci USA 99, 6047-6052 Nanoparticle methods such as those descnbed by Schiffelers et al (2004) Nucleic Acid Ret, 32 el 49 and fusion protein methods such as described by Song et al (2005) Nature Bwtechnol 23 709 717 are also useful
For further guidance concerning inhibitory RNAs, see e g , Lau et al (2003) Scientific American, pp 34-41 , McManus et al (2002) Nature Reviews Genetics 3, 737 747, and Dykxhoorn et al (2003) Nature Reviews Molecular Cell Biology 4, 457-467 For further guidance regarding methods of designing and preparing siRNAs, testing them for efficacy, and using them in methods of RNA interference (both in vitro and in vivo), see, e g , Allshire (2002) Science 297, 1818- 1819, Volpe et al (2002) Science 297, 1833-1837, Jenuwein (2002) Science 297, 2215-2218, Hall et al (2002) Science 297 2232-2237, Hutvagner et al (2002) Science 297, 2056-60, McManus et al (2002) RNA 8, 842-850, Reinhart et al (2002) Gene & Dev 16. 1616- 1626, Reinhart et al (2002) Science 297, 1831 , Fire et al (1998) Nature 391, 806-811, Moss (2001 ) Curr Biol JJ_, R772-5, Brummelkamp et al (2002) Science 296, 550 3, Bass (2001) Nature 4JJ.428-429, and Elbashir et al (2001) Nature 4JJ., 494 498, USP 6,506,559, US patent application 20030206887, and PCT applications WO99/07409, WO99/32619, WO 00/01846, WO 00/44914, WO00/44895, WO01/29058, WO01/36646, WO01/75164, WO01/92513, WO 01/29058, WO01/89304, WOO 1/90401 , WO02/16620, and WO02/29858 Ribozymes and siRNAs can take any of the forms, including modified versions, described above for antisense nucleic acid molecules
In one embodiment, an interfering nucleic acid is a double-stranded RNA (e g , an siRNA), one of whose strands comprises (or consists essentially of) one of the sequences represented by SEQ ID NOS 1 -6, or an active variant thereof, or a complement of one of those sequences
Active vaπants (e g , length vaπants, including fragments, and sequence vaπants) of the nucleic acid-based inhibitors discussed above are included in the invention An "active" vaπant is one that retains a measurable amount of an activity (such as the ability to inhibit expression) of the inhibitor from which it is deπved With regard to length vaπants, an antisense nucleic acid or siRNA may be of any length that is effective for inhibition of a gene of interest Typically, an antisense nucleic acid is between about 6 and about 50 nucleotides (e g , between about 10 and 30 nucleotides, or at least about 12, 15, 20, 25, 30, 35, 40, 45 or 50 nt), and may be as large as about 100 to about 200 nucleotides, or larger Antisense nucleic acids having about the same length as the gene or
coding sequence to be inhibited may be used The length of an effective MRNA IS generally between about 19 bp and about 29 bp in length, (e g , about 19, 21, 23, 25, 27 or 29 bp), with shorter and longer sequences being acceptable Generally, siRNAs are shorter than about 30 bp, to prevent eliciting interferon effects For example, an active variant of an siRNA having, for one of its strands, the sequence of SEQ ID NO 1 , SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5 or SEQ ID NO 6 can lack base pairs from either, or both, of the ends of that double stranded RNA, or it can compπse additional base pairs at either, or both, ends of the double stranded RNA, provided that the total of length of the siRNA is between about 19 and about 29 bp, inclusive One embodiment of the invention is an siRNA, one of whose strands consists essentially of a sequence represented by SEQ ID NO. l , SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5 or SEQ ID NO 6
The term "consists essentially of," when used in the context of biopolymers, refers to a sequence which is intermediate between the specific number of residues (amino acids or nucleotides) encompassed by the term "consisting of" and the longer unspecified length encompassed by the term "comprising " Residues in addition to the residues encompassed by "consisting of" language do not affect the basic and novel characteristics (e g , in the present case, the ability to inhibit VEGF-A or VEGF-A receptor expression and/or activity) of the molecule encompassed by the "consisting of" language
As for sequence variants, in general it is preferable that an inhibitory nucleic acid, such as an antisense molecule, a πbozyme (the recognition sequences), or an siRNA, comprises a strand that is complementary (100% identical in sequence) to a sequence of a gene that it is designed to inhibit However, 100% sequence identity between the nucleic acid and the target gene is not required to practice the present invention Thus, the invention has the advantage of being able to tolerate naturally occurring sequence variations that might be expected due to genetic mutation, strain polymorphism, or evolutionary divergence Alternatively, the variants may be artificially generated Nucleic acid sequences with, e g , small insertions, deletions, and single point mutations relative to the target sequence can be effective for inhibition
The degree of sequence identity may be optimized by sequence comparison and alignment algorithms known in the art (see Gπbskov and Devereux, Sequence Analysis Primer, Stockton Press, 1991, and references cited therein) and calculating the percent difference between the nucleotide sequences by, for example, the Smith-Waterman algorithm as implemented in the BESTFIT software program using default parameters (e g , University of Wisconsin Genetic Computing Group) Greater than about 90% sequence identity (e g , about
95%, 98% or 99%), or even 100% sequence identity, between the inhibitory nucleic acid and the portion of the target gene is preferred
Alternatively, an active vaπant of an inhibitory nucleic acid of the invention is one that hybridizes to the sequence it is intended to inhibit under conditions of high stringency For example, the duplex region of an siRNA may be defined functionally as a nucleotide sequence that is capable of hybridizing with a portion of the target gene transcπpt under high stπngency conditions (e g , 400 rnM NaCl, 40 mM PIPES pH 6 4, 1 mM EDTA, 70°C hybridization for 12-16 hours, or equivalent conditions), followed generally by washing
A skilled worker can readily test a candidate siRNA or antisense vaπant molecule to determine if it is inhibitory
As used herein, an "isolated" RNA or DNA is one that is in a form not found in its original environment or in nature, e g , more concentrated, more purified, separated from at least one other component with which it is naturally associated, in a buffer, etc
In another embodiment, the inhibitory agent inhibits an activity of the VEGF-A or a
VEGF A receptor Examples of such inhibitors of activity (antagonists) include, e g , an antibody specific for VEGF-A or VEGF A receptor, a peptide or oligonucleotide which binds to the polypeptide of interest and effectively eliminates its function, or a small molecule pharmaceutical agent Another potential antagonist is a closely related protein which binds to a VEGF receptor but inhibits its function rather than activating it For example, an antagonist of VEGFR2 receptor could be a protein that is closely related to VEGFR2, but is an inactive form of the polypeptide and thereby prevents the action of VEGFR2 Examples of these antagonists include a negative dominant mutant of the VEGFR2 polypeptide, wherein one chain of the hetero dimeric form of VEGFR2 is dominant and is mutated such that biological activity is not retained An example of a negative dominant mutant includes a truncated version of a dimeπc VEGFR2 which is capable of interacting with another dimer to form wild type VEGFR2, but the resulting homo-dimer is inactive and fails to exhibit characteristic VEGFR2 activity
One aspect of the invention is an antibody which is generated against a protein molecule or a peptide fragment of VEGF-A or a VEGF A receptor As used herein, the term "antibody" is used in the broadest sense and encompasses single monoclonal antibodies, polyclonal antibodies, chimenc antibodies, humanized antibodies, single-chain antibodies and antibody fragments (e g , Fab, F(ab'), Fv) Antibodies are designed to block the activity of VEGF A or a VEGF A receptor, e g as it relates to the stimulation of hyperplastic epithelium in sinonasal polyp tissue The terms a 'blocking"antibody or a "neturahzing" antibody, as used herein,
means an antibody that can inhibt the function of a defined target of interest The antibodies can be produced by standard antibody technologies (e g , monoclonal antibody technologies) and can be humanized if successful in blocking the VEGF-A or VEGF-A receptor activity If desired, candidate antibodies first can be shown in vitro to suppress VEGF-A or VEGF-A receptor activity, and then tested in vivo using a conventional animal model Those antibodies that successfully inhibit VEGF-A or VEGF-A receptor activity can be further processed to be humanized and ready for use in humans A preferred antibody of the invention is highly specific (lmmunospecific) for VEGF-A or a VEGF-A receptor
Guidance for producing antibodies (or other agents) specific for VEGF, NP-I and VEGF receptors is provided, e g , in the following US patents and patent publications These and other references cited herein which provide guidance for performing methods related to the present invention are incorporated by reference herein in their entirety 5,730,977 Anti-VEGF human monoclonal antibody
5,840,301 Methods of use of chimeπzed, humanized, and single chain antibodies specific to VEGF receptors
5,874,542 Single chain antibodies specific to VEGF receptors 6,342,219 Antibody compositions for selectively inhibiting VEGF 6,884,879 Anti-VEGF antibodies
7,335,357 Antagonists of neuropilin receptor function and use thereof 7,375,193 Anti-VEGF antibodies
7,5312,172 Methods of treating diseases with a VEGF antagonist
7,534,878 Composition and method of RNAi therapeutics for treatment of cancer and other neovascularization diseases
7,576,189 Antibodies to human vascular endothelial growth factor 2 and methods of using the same
20060115477 Neuropilin- 1 inhibitors 20080213268 Neuropilin Antagonists
Another class of agents that inhibit the function of VEGF-A or a VEGF-A receptor are small molecules which bind to and occupy the active site of the polypeptide, thereby making the catalytic suite inaccessible to substrate wuch the normal biological activity is prevented Examples of small molecules include, e g , small peptides or peptide-hke molecules, and small organic compounds, which can include both synthetic compounds and naturally occurring compounds
A number of inhibitors of the expression or the activity of VEGF-A or a VEGF A receptor have been proposed and/or developed for the treatment of conditions which are mediated by VEGF other than chronic inflammatory respiratory disorders Such conditions include, e g , anti-tumor therapies, treatment of macular degeneration, and of other conditions mediated by angiogenesis It is expected that such agents would also be effective against chronic inflammatory respiratory disorders such as CRSwNP It might be necessary to modify the formulations, dosages and routes of administration of these agents in order to optimize the treatment of chronic inflammatory respiratory disorders Suitable modifications would be evident to a skilled worker, using routine, conventional procedures For example, suitable formulations are descπbed in Remington's Pharmaceutical Sciences, 18th ed , Mack Publishing Company, 1990
Among the agents that have been developed for treating other indications are the following an RNA aptamer, such as pegaptanib, a partial or full-length antibody, such as rambizumab or bevacizumab, a VEGF receptor decoy, such as VEGF Trap (see, e g , USP 7,541,172), small interfering RNA-based therapies, such as a microRNA or an siRNA, including the siRNAs descπbed herein, microRNAs, bevasiramb, or AGN21 1745, a tyrosine kinase inhibitor, such as vatalanib, pazopamb, TG 100801, TG 1O1O95, AG013958 or AL39324, or a blocking peptide For example, one can use a blocking peptide against the VEGF receptors NPl and/or VEGFR2, such as described in Barr et al (2005) Br J Cancer 92, 328-333 A number of considerations are generally taken into account in designing delivery systems, routes of administration, and formulations for inhibitory agents of the invention The appropriate delivery system for an inhibitory agent of the invention will depend upon its particular nature, the particular clinical application, and the site of drug action
Among the methods which have been used successfully to deliver siRNAs are, e g , plasmid vectors, retrovirus vectors, including oncoretrovirus vectors and lentivirus vectors, and hydrodynamic "high pressure" delivery
In one embodiment of the invention, when treating a subject, an inhibitory agent is administered by systemic intravenous (IV) or by a local intranasal route, such as an intranasal spray, a metered dose inhaler, a nebulizer, or a dry powder inhaler Formulations for delivery by a particular method (e g , solutions, buffers, and preservatives, as well as droplet or particle size for intranasal administration) can be optimized by routine, conventional methods that are well- known in the art For inhibitory agents that are in the form of aerosol formulations to be administered via inhalation, the aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen or the like
The dose of an agent of the invention, or composition thereof, administered to an animal, particularly a human, in the context of the present invention should be sufficient to effect at least a detectable amount of a therapeutic response in the individual over a reasonable time frame (e g , an anti-inflammatory- or antiproliferative effective amount) The exact amount of the dose will vary from subject to subject, depending on the species, age, weight and general condition of the subject, the seventy or mechanism of any disorder being treated, the particular agent or vehicle used, its mode of administration and the like The dose used to achieve a desired effect in vivo will be determined by the potency of the particular agent employed, the pharmacodynamics associated with the agent in the host, the severity of the disease state of infected individuals, as well as, in the case of systemic administration, the body weight and age of the individual The size of the dose also will be determined by the existence of any adverse side effects that may accompany the particular inhibitory agent, or composition thereof, employed It is generally desirable, whenever possible, to keep adverse side effects to a minimum Dosages for administration of an inhibitory agent of the invention can be in unit dosage form, such as a tablet or capsule The term "unit dosage form" as used herein refers to physically discrete units suitable as unitary dosages for human and animal subjects, each unit containing a predetermined quantity of an inhibitor of the invention, alone or in combination with other therapeutic (e g , anti inflammatory) agents, calculated in an amount sufficient to produce the desired effect in association with a pharmaceutically acceptable diluent, carrier, or vehicle
The specifications for the unit dosage forms of the present invention depend on the particular agent of the invention, or composition thereof, employed and the effect to be achieved, as well as the pharmacodynamics associated with each polypeptide, or composition thereof, in the host In some embodiments, the dose administered is an "anti inflammatory effective amount or an "anti proliferative effective amount '
One skilled in the art can easily determine the appropriate dose, schedule, and method of administration for the exact formulation of the composition being used, in order to achieve the desired response in the individual patient One embodiment of the invention is a kit useful for any of the methods disclosed herein
Such a kit can compπse one or more isolated inhibitors of the invention A device, composition, or other means for administering the inhibitor to the nasal tract can also be included A kit suitable for a therapeutic treatment in a subject may further compnse a pharmaceutically acceptable carrier and, optionally, a container or packaging material Among other uses, kits of
the invention can be used in experiments, e g to study mechanisms by which VEGF acts as an epithelial cell mitogen, etc A skilled worker will recognize components of kits suitable for carrying out any of the methods of the invention
Optionally, the kits comprise instructions for performing the method, and/or a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products (such as the FDA), which notice reflects approval by the agency of manufacture, use or sale for human administration In addition, agents in a kit of the invention may comprise other therapeutic compounds, for combination therapy Other optional elements of a kit of the invention include suitable buffers, pharmaceutically acceptable carriers, or the like, containers, or packaging matenals The reagents of the kit may be in containers in which the reagents are stable, e g , in lyophihzed form or stabilized liquids The reagents may also be in single use form, e g , in single dosage form for use as therapeutics, or in single reaction form for diagnostic use
In the foregoing and in the following examples, all temperatures are set forth in uncorrected degrees Celsius, and, unless otherwise indicated, all parts and percentages are by weight
EXAMPLES I. Methods Human Subiects
All subjects studied were enrolled after obtaining informed consent under a Johns Hopkins Medicine Institutional Review Board-approved human subjects research protocol The CRSwNP patients were defined by historical, endoscopic, and radiographic criteria, and by meeting the definition of the Ameπcan Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) Chronic Rhinosinusitis Task Force Specifically, CRS alone patients had continuous symptoms of rhinosinusitis as defined by the Task Force report for greater than 12 consecutive weeks, associated with computed tomography of the sinuses revealing isolated or diffuse sinus mucosal thickening and or air fluid level CRSwNP subject was defined by endoscopic exam findings of polyps and post-treatment CT scan confirmation of persistent bilateral and diffuse paranasal sinus mucosal thickening Surgery for CRSwNP patients was only performed if a patient's symptoms and radiographic findings failed to resolve despite at least 6 weeks of treatment with oral antibiotics, topical corticosteroids, decongestants, and/or mucolytic agents in accordance with the accepted standards of medical care However, CRSwNP subjects, CRS alone, and normal control subjects who were chosen for these studies
had no immediate preoperative steroids within 14 days prior to obtaining any specimen In addition, CRSwNP subjects had no intranasal glucocorticoid exposure duπng the immediate one month post operative period Normal control subjects were defined as those individuals failing to meet criteria for CRS as defined above and having no evidence of sinus disease These subjects were normal healthy volunteers Normal control sinus tissue was obtained as discarded sinus tissue from non CRS patients who were undergoing endoscopic surgery for transphenoidal hypophysectomy or cerebrospinal fluid leak repair As a secondary characteπstics, atopic status was defined by puncture skin test positivity using 22 allergens as previously descnbed (PS Creticos, In vivo provative testing for IgE mediated disease New York Marcel Dekker, 1999) These include cat, dog, mouse and rat danders, short ragweed, mugwort, rye grass, Bermuda grass, oak, birch, dust mites (Dermatophagoides pteronyssinus and Dermatophagoides faπnae), cockroach (Blatella germanica, Peπplaneta ameπcana, and Blata oπentahs), and mold (Alternaπa alternata, Aspergillus fumigatus, Cladosporium herbarum, Curvulana, Dreschella, Fusaπum, and Rhizopus (ALK Laboratories) Phosphate buffered saline and histamine was used as negative and positive controls, respectively The skin test response is measured 15 mm after application on the forearm by puncture with a bifurcated needle An impπnt of the perimeter of the wheal and erythema will be made using 3M Transpore tape transferred onto a sheet of paper for permanent documentation The two cross diameters were measured to quantitate the size of the wheal and the erythema A positive test is defined as an average wheal diameter greater than or equal to 3 mm above the saline control Subjects with asthma were defined as those who 1) have a physician diagnosis of asthma as descnbed by NHLBI expert panel 3 report (Expert panel report 3 (epr-3) Guidelines for the diagnosis and management of asthma-summary report 2007 J Allergy Clin Immunol 2007, 120 S94-138) where subjects who display FEV 1/FVC ratio less than 0 7 measured pπor to optimization of asthma control and either one of the following conditions following administration of a bronchodilator (a) >12% improvement in FEVl (or FVC) or (b) an absolute improvement of >0 2 L, and 2) have been placed on prescription medication for asthma (such as bronchodilators, inhaled steroids, or oral steroids) In addition, CRSwNP subjects with asthma were further classified with respect to level of asthma control by ( 1) FEVl values measured within one month of enrollment and (2) number of exacerbations requiring oral systemic corticosteroid treatment to control asthma symptoms as defined by the NHLBI expert panel 3 report, referred to above
Collection of nasal scrapings Nasal epithelial cells were collected from the inferior nasal turbinate by curettage with a steπle nasal cytology brush (Wampole, Harnsburg, PA) and were rinsed twice in a sterile Eppendorf tube containing 5 ml of lactated Ringers solution as previously descπbed (Kim et al (2005) Am J Respir Cell MoI BwI 33, 280-289) The cells are centπfuged at 300 x g for 5 mm at room temperature Each nasal scraping specimen yields 1 2 x Iθ6 cells, of which >95% are epithelial cells by Wright stain cell count
Collection of nasal lavage samples Nasal lavage was collected according to previously descπbed methods (Nacleπo et al (1983) Am Rev Respir Dn, 128,597 602) Lavages were performed with steπle saline solution prewarmed to 37° C Bnefly, 5 ml of saline was instilled into each nasal cavity a pipette with the head extended, while the patient holds his/her breath for 10 seconds Then, the patient is asked to tilt his/her head forward to allow the saline to drip into a collection basin The lavage fluid was processed by spinning at 3600 rpm for 15 minutes, ahquoted and frozen in 80ϋC for detection of VEGF, other growth factors, and total protein
Culture of PNEC Epithelial cells cultured from nasal scrapings were cultured in bronchial epithelial basal medium (Biosource, Camaπllo, TX) on collagen coated plates as previously descnbed (Kim et al (2005, supra), Heinecke et al (2008) J Allergy Clin Immunol 121 ,1 155 1 160, Kim et al (2000) J Immunol 165, 3384 3392) Cultures, of PNEC routinely were 99-100 % cytokeratin positive staining at the time of harvest PNEC were routinely used for all in vitro studies at first or second passage only For functional studies measunng cell growth and apoptosis, the cells were incubated for varying lengths of time with recombinant VEGF (R&D, Minneapolis, MN, 100 ng/ml, (Conn et al (1990) Proc Natl Acad Su U S A 87, 2628 2632), or antibody that has been previously shown to functionally block its target anti VEGF blocking antibody (R&D, 1 ug/ml), anti NP-I blocking antibody (Miltenyi, Biotech, Auburn, CA, 1 ug/ml, (Wilgus et al (2005) Am J Pathol 167, 1257-1266), anti VEGFRl blocking antibody (R&D 10 ug/ml (Ferrara et al (1997) Endocr Rev .18, 4 25), anti-VEGFR2 blocking antibody (R&D, 1 ug/ml, (Giuliani et al (2003) Blood 102, 638 645), recombinant EGF (R&D, 50 ng/ml, (Beck et al (2006) J Immunol 177, 3344-3354), or irrelevant isotype control antibody (eBioscience, San Diego, CA)
Flow cytometry The monoclonal antibodies against VEGF (R&D, Minneapolis, MN) and NPl (Miltenyi Biotech, Auburn, CA) used for flow cytometry were analyzed as previously described with a FACS Calibur flow cytometer (Becton Dickinson, Mountain View, CA) using CellQuest
software (Kim et al (2005), Heinecke et al (2008), and Kim et al (2000), all supra ) The viability of PNEC at the time of cell harvest was assessed by propidium iodide exclusion Fluorescence was determined on all cells for each sample after debris, dead cells and aggregates were excluded by forward angle and side scatter gating Mean fluorescence intensity (MFI) was compared with control staining using an irrelevant isotype-matched mouse monoclonal antibody For each sample, at least 10,000 events were collected, and histograms were generated Data are usually expressed as means + SEM
lmmunohistochemistry Surgical sinonasal tissue was immediately fixed in 4% formaldehyde in phosphate buffered saline (PBS, 4°C, 4 hr) and then rinsed with PBS Antibody to VEGF (R&D), NP-I (Miltenyi), VEGFRl (R&D), VEGFR2 (R&D), phospho-VEGFR2 (Santa Cruz Biotechnology, Santa Cruz, CA), or irrelevant IgG isotype (eBioscience) control was performed as previously descnbed (Kim et al (2005), Heinecke et al (2008), and Kim et al (2000), all supra ) To assure that detection of positive staining was performed in a standardized and uniform manner between tissue samples, staining was routinely performed in sets of tissues using a specimen from each of the two patient groups Each round of staining was exposed to diaminobenzidine for a fixed duration to the standardize time for color development The slides were evaluated with a bπghtfield microscope (Olympus BX-50) equipped with a camera (Q Imaging Retiga Exi or Spot ET-3 CCD camera) and a micrograph field of view of the entire stained section Image Pro Lab imaging software (Microsoft) was used to analyze areas of positive staining in each digitized micrograph All epithelial cells were selected (from the basement membrane to the luminal surface) as the region of interest (ROI) in each image of the immunohistocherriically stained (e g VEGF) section A standard size of ROI surface area was used and applied to all images Simple bi-level thresholding, based on criteria for positive staining was set by a trained personnel who is blinded to the specimen phenotype This threshold window was set and applied to all analyzed images, the number of nuclei was also counted in the ROI The software measurement of the area of positive immunostaining and number of nuclei in the ROI are transferred to an Excel spreadsheet for statistical analysis and determination of the average intensity area per cell (total area of positive immunostaining divided by number of nuclei) The data are expressed as intensity of staining per cell
ELISA assay for growth factors VEGF, EGF, and TGFβl from nasal lavages and cell supernatants were measured using ELISA kits from R&D according to manufacturers instructions The minimum detectable concentration of was typically 5 0 pg/ml Assay of each
sample was performed in triplicate Data are expressed per ug of total protein that was measured by Bradford assay (Bio Rad, Hercules, CA)
Determination of PNEC growth to culture confluence Two hundred thousand cells/ well were plated onto collagen coated 6 well plates Attainment of culture confluency was assessed under 4OX power phase contrast light microscopy An estimate of confluency was determined by averaging inspection of 5 separate fields 0, 90, 180, 270 degree and center of each well Confluency was defined when a minimum average of 90% has been reached Each sample assay was performed in triplicate and the analysis blinded to the subject group
Cyquant cell proliferation assay Cell proliferation was assayed using the Cyquant cell proliferation assay (Molecular Probes) Cells were seeded at 5X103 cells/well and grown to 50% confluence in 96-well plates in serum-free bronchial EC growth medium (Cambrex), deprived of EGF for 24 hrs before challenge to synchronize cell growth, and subsequently stimulated according to the experimental protocols As per the manufacturer's instructions, at the end of the experiment, the cell supernatants were aspirated and the cells were lifted by trypsimzation Cell lysis was performed by two sequential freeze-thaw cycles Standard curves were executed with each run of the assay according to manufacturers instruction Cells were then incubated for 5 mm at room temperature with Cyquant lysis buffer containing the Cyquant GR fluorescent dye Fluorescence was measured using a Cytofluor 4000 fluorescence reader (Applied Biosystems (Life Technologies) Each experimental condition was assessed in quadruplicates
siRNA transfection PNEC was grown to 75% confluence and transfected with indicated concentration of target gene NPl (100 nM), negative control, or rhodamine-tagged control siRNA (Qiagen, Valencia, CA) using RNAimax transfection reagent made up in OptiMem buffer (1 1 volume) as directed by vendor (all reagents from Invitrogen) PNEC were then exposed to siRNA/RNAimax in cell culture media without antibiotics (1 3) for 24 hours at 37° C Viability is monitored by light microscopy Transfection efficiency was assessed by measuring average % of rhodamine positive cells per field X 4 sampled fields at 1OX and 4OX magnification using fluorescent microscopy
Statistical Analysis All data are expressed as mean + SEM Comparison between the phenotypic classes and control groups was analyzed using Kruskal Wallis Test Comparison of
in vitro quantitative data between multiple treatment conditions was determined using ANOVA and post hoc Bonferroni Test.
Table 1. Characteristics of Human Subjects
broπchodilator challenge
Ere post
Medications FEV1 (liters, oral
Skin at time of FEV1 % corticosteroid
Subject Phenotype Gender Age Test enrollment Asthma FEV1/FVC (liters) improvement) dose per year
1 CRSwNP M 55 0 85 3 79 3 83 (1%) 0
ICS/LABA
2 CRSwNP M 43 + + 0 64 4 37 5 02 (16%) 2 antihistamines
ICS/LABA antihistamines
CRSwNP 20 0 7 3 2 3 78 (18%) montelukast albuterol
ICS/LABA antihistamines
CRSwNP 46 0 65 2 83 3 20 (13%) montelukast, albuterol
ICS/LABA
5 CRSwNP M 80 0 55 2 65 3 00 (13%) 5 montelukast
6 CRSwNP F 32 0 87 2 2 2 1 (0%) 0
7 CRSwNP M 40 ICS/LABA + 0 57 3 85 4 08 (6%) 1
8 CRSwNP F 50 ICS/LABA + 0 68 1 83 2 1 (15%) 8
9 CRS F 68 antihistamines antihistamines
10 CRS M 46 montelukast (for rhinitis)
11 CRS M 73
12 CRS M 66
13 CRS M 43 antihistamines,
14 CRS F 29 + montelukast (for rhinitis)
15 Control M 35
16 Control F 58
17 Control M 27
18 Control M 30
19 Control F 24
ICS=ιnhaled corticosteroid, LABA= long acting beta agonist
II. Results
A VEGF is elevated in nasal lavages of CRSwNP
To examine the role of growth factors in upper airway remodeling observed in sinonasal polyposis, we compared the levels of VEGF, EGF, and TGFβl in nasal lavage aspirates from subjects with CRSwNP, CRS alone and normal control patient groups Patient characteristics are given in Table 1 All subjects had a negative history of glucocorticoid usage (either intranasal or oral) at least 2 weeks pnor In addition, CRSwNP subjects had no glucocorticoid exposure during the immediate one-month post-operative period Antihistamines were withheld 48 hours pnor to skin testing and then resumed as medically indicated All other medications, as listed in Table 1 , including inhaled corticosteroids (indicated for asthma) and leukotπene antagonists (indicated for asthma or rhinitis), were continued through the study The specific monoclonal antibodies used in this assay (R&D Systems) have been shown to detect all soluble human VEGF (including VEGF165 and VEGF121), EGF, and TGFβl, respectively Results in Figure 1 Panel A demonstrate that subjects with CRSwNP display significantly greater than 7 fold higher levels of VEGF protein in nasal lavages (177+35 pg/ug protein) compared to normal control subjects (24+3 pg/ug) or CRS subjects without sinonasal polyposis (25+2 pg/ug) In addition, removal of polyps and achievement of quiescent disease in CRSwNP subjects resulted in a dramatic reduction of VEGF levels comparable to that of normal control values (see Figure 1 Panel B) Total protein levels in nasal lavages did not differ significantly between the 3 patient groups In contrast to VEGF, there was no significant difference in the level of EGF measured in nasal these lavages between the 3 patient groups Additionally, we failed to detect any measurable soluble TGFβl in nasal lavage aspirates
Examination of secondary characteristics of CRSwNP subjects revealed that only 3/8 CRSwNP subjects were skin test positive However, the majority of the CRSwNP subjects (6/8) examined had asthma Furthermore, 5/8 CRSwNP subjects had poorly controlled asthma as defined by (1 ) FEV l < 60% predicted or (2) at least 2 doses per year of oral corticosteroid treatment for asthma exacerbations
B VEGF is overexpressed in vivo and in vitro in CRSwNP To confirm the presence of VEGF on epithelium in sinonasal polyps, immunohistochemical staining was performed on sinus tissue surgical samples using monoclonal antibodies against VEGF, and isotype control IgG Sinonasal tissue from CRSwNP (maxillary sinus polyp) and normal control subjects (maxillary or sphenoid sinus) were tested The staining intensity of digitized images of epithelial cells was objectively assessed by Image
Pro software (Microsoft) and expressed as intensity units per epithelial cell using similar sized sampling areas Firstly, Figure 2A (and in Figure 3) shows that epithelial cell hyperplasia, which is characteristic of CRSwNP, is uniquely present in CRSwNP, and absent from normal control subjects Data show that VEGF was detected in representative human sinonasal tissue The irrelevant IgG isotype negative control with secondary antibody shown in the inset demonstrates no nonspecific brown staining in the epithelial layer in both subject groups As additional controls, staining performed in the absence of primary or secondary antibody yielded no significant signal The intensity of staining within the epithelium varied between subject groups and the sinonasal polyp from CRSwNP subject demonstrated significantly increased staining intensity for VEGF especially within the epithelial cell layer as compared to sinonasal tissue from maxillary sinuses of control subjects (p<0 012) VEGF staining was observed in the epithelial cell layer, but not exclusively
Since we found VEGF to be highly expressed on epithelial cells in vivo, we wanted to know if VEGF was detectable on the surface of nasal epithelial cells in vitro VEGF is known to exist on the cell surface residing within an extracellular pool In addition, VEGF is known to exist in a membrane bound form The results shown in Figure 2B (left) display flow cytometric findings using specific monoclonal antibodies to VEGF on nasal epithelial cells taken from infeπor turbinates which were expanded in cell culture from a normal control subject The anti VEGF antibody used detects all isoforms of VEGF, including membrane bound VEGFl 89 The results demonstrate fairly unimodal detection of robust levels of cell surface expression of VEGF (94% positive) on PNEC from a normal control subject Figure 2B (middle) compares VEGF cell surface expression on PNEC taken from infenor turbinates from control and CRSwNP subjects The data demonstrate that cell surface expression of VEGF from CRSwNP is increased by ~2 fold (p<0 05) VEGF is also known to be secreted by cells in the form of two soluble isoforms VEGFl 65 and VEGFl 21 To examine whether PNEC from CRSwNP subjects produce elevated levels of soluble VEGF, we compared soluble VEGF (both VEGF 165 and VEGF121) released into cell supernatants of PNEC from CRSwNP and control subjects Wells from a 6 well plate were seeded with identical cell numbers of PNEC from individual subject donors and grown to 90% confluence Cell supernatants were assayed for VEGF using ELISA The results in Figure 2C demonstrate that PNEC from CRSwNP subjects expressed, produced and released greater than 3 fold higher levels of soluble VEGF into the cell supernatant as compared to PNEC from normal control subjects (p<0 02) These data demonstrate that both soluble and cell surface VEGF is over expressed by PNEC from CRSwNP subjects
C VEGFR2, phospho VEGFR2, and NPl are abundantly expressed by epithelial cells in sinonasal tissue
Because VEGF was found to be so abundantly present in epithelium of sinonasal polyp tissue, we hypothesized that VEGF has a biological function on these cells We hypothesized that the receptors for VEGF are also present on nasal epithelium VEGFR2 is known to exhibit robust tyrosine kinase activity and auto and transphosphorylation when activated by VEGF hgand binding To examine whether activation of the VEGF signaling pathway occurs in sinonasal epithelium in vivo, we looked for the presence of phosphorylation of VEGFR2 by performing immunostaining for VEGFR2 and phospho-VEGFR2 Figure 3 A demonstrates that VEGFR2 was detected in human sinonasal tissue from CRSwNP subjects, but barely detectable in normal control subjects (p<0 04) Additionally, there was markedly elevated staining of phospho VEGFR2 in polyps of subjects with CRSwNP as compared to specimens from normal control subjects (p<0 04) Interestingly, we detected robust constitutive staining of neuropilin-1 (NPl), the co receptor for VEGF, in sinonasal epithelium from both patient groups These studies are the first to report expression of NPl on human airway epithelial cells In vitro studies, shown in Figure 3B, demonstrated that cell surface NPl is expressed at high constitutive levels by PNEC (58% positive) derived from control subjects Furthermore, both in vivo and in vitro expression of NPl appears to be unaffected by disease phenotype These data show that, not only is the hgand VEGF abundantly present in diseased sinonasal epithelium, but that at least one of the receptors which is necessary for signaling is also present in active form In addition, NPl has been newly identified to be abundantly expressed on airway epithelial cells of sinonasal tissue in both patient groups
D PNEC from CRSwNP subiects display elevated growth rates in vitro
Duπng the course of expanding PNEC in culture from nasal scrapings, we observed that epithelial cells harvested from CRSwNP subject displayed a faster rate of growth as compared to normal control cells, consistent with their hyperplastic histologic appearance Therefore we undertook efforts to systematically examine the growth and survival of nasal cells deπved from CRSwNP subjects and compare them to nasal epithelial cells deπved from controls We standardized culture conditions to optimize recovery of cells by minimizing time from harvest to seeding as well as the initial cell seeding concentration and assessed the number of days to culture confluency The results Figure 4A demonstrate that sinonasal epithelial cells deπved from CRSwNP have a 2 3 fold increase in rate of cell growth to confluency as compared to
normal control PNEC, when grown under identical seeding concentrations and conditions (p<0 008) To examine this further, we directly quantitated net cell growth using Cyquant dye fluorometπc quantification of DNA (Figure 4B) After 96 hours in culture, PNEC from infeπor turbinates of CRSwNP subjects displayed a greater than 2 fold faster growth rate as compared to PNEC from control subjects (p<0 005) In CRSwNP subjects, PNEC obtained directly from the polyps by nasal brushing (cell count at 96 hours 10584+1249, n=5) demonstrated similar growth rates to PNEC harvested from the infeπor turbinate (see Figure 4 Panel B, 9162+1331, n=8) and demonstrated elevated growth rates compared to PNEC from control subjects (p<0 006, 4049+919, n=5) Because elevated growth rate of epithelial cells from CRSwNP subjects was similarly observed in cells harvested from either polyps or inferior turbinates, compaπson of in vitro PNEC behavior between CRSwNP and control subjects was performed using PNEC from inferior turbinates so that matched comparison of cell types could be made
E VEGF dnves human nasal epithelial cell growth Given the excessive levels of VEGF from sinonasal epithelium derived from CRSwNP, we hypothesized that VEGF may be acting in an autocrine fashion to increase the growth rate of epithelium from CRSwNP To address this notion, we examined the effect of functional blocking antibodies to VEGF and to components of VEGF signaling pathway on proliferation rates of PNEC in vitro Synchronization of the cell cycle was first performed by withdrawal of basal EGF from the media All conditions had no exogenous VEGF supplementation Figure 5A shows that exposure of blocking antibody to VEGF hgand for 96 hours resulted results in a 34% inhibition of cell growth (p<0 05) Exposure to blocking antibody against VEGFRl or VEGFR2 alone resulted in a modest 12% inhibition in cell proliferation rates However, exposure to functional blocking antibody against co-receptor NPl resulted in a 43% inhibition of cell growth (Fig 5B) (p<0 05) The combination of blocking antibody to NPl and anti VEGFRl and /or anti VEGFR2 antibody resulted in a greater decline in cell proliferation to 50% (Figure 5C, p<0 02) Exposure to IgG control antibody had no effect Thus the effect of exposure to multiple blocking antibodies to VEGF receptors was additive In addition, exposure to recombinant EGF had no significant effect on cell growth up to 96 hours The results of this analysis were highly reproducible in that the standard deviation of quadruplicate measurements obtained with this assay was small (<10% of measured values) In addition, the standard deviation between the expeπments (n=5 donor subjects) ranged between 12-27% of the mean growth rates Cell proliferation at 96 hours for each condition was also assessed using BrdU
incorporation (Calbiochem) and resulted in identical patterns of cell growth These results demonstrate that VEGF functions in an autocrine manner to promote epithelial cell growth
F VEGF inhibits apoptosis through NPl To examine whether VEGF may also function as a prosurvival factor, we examined the effect of functional blocking antibodies to components of VEGF pathway on induction of apoptosis of PNEC in vitro Apoptosis was determined by flow cytometric detection of annexin V-FlTC staining Figure 6A shows that 48 hour exposure to blocking antibody to NPl resulted in a significant 2 5 fold increase in apoptosis of PNEC from CRSwNP subjects (p<0 02) Exposure to blocking antibody to receptor VEGFRl or VEGFR2 resulted in no significant increase in apoptosis of PNEC The combination of blocking antibody to NPl with anti- VEGFRl and/or anti VEGFR2 antibodies resulted in the same level of apoptosis observed with anti-NPl alone (p<0 01, p<0 02 and p< 0 05, respectively) Figure 6B shows the matching light microscopic appearance of cells under blocking antibody conditions Cells exposed to anti-NPl or the combination of anti-NPl with anti-VEGFRl and/or anti-VEGFR2 demonstrated significant cell membrane blebs indicative of morphologic evidence of increased cell death, as compared to control conditions or of cells exposed to IgG control antibody, or to blocking antibody to receptors VEGFRl or VEGFR2 alone These results demonstrate that VEGF functions to inhibit apoptosis in PNEC through NPl
G VEGF functions to autoregulate its own expression in PNEC
We proposed that an additional key function of VEGF from nasal epithelial cells in CRSwNP is to regulate autocrine expression of itself To test this, we examined the effect of blocking VEGF receptor function on soluble VEGF produced and secreted by PNEC in vitro VEGF levels in cell supernatants were measured by ELISA as described in Methods Firstly, Figure 7 shows that PNEC from CRSwNP produce a remarkable level of constitutive soluble VEGF in the nanomolar range In addition, Figure 7 shows that exposure of PNEC from CRSwNP subjects to blocking antibodies against VEGFRl or VEGFR2 alone resulted in minimal change (20% and 12% decrease) in soluble VEGF from cell supernatents However, exposure to anti NPl resulted in an enhanced 33% significant inhibition of soluble VEGF expressed by PNEC (p<0 05) Addition of anti-VEGFRl and/or anti-VEGFR2 to anti-NPl produced no further inhibition of soluble VEGF expression (42%, 36%, and 34% decline respectively, p<0 05 for each condition) Thus receptor blockade of VEGF function results in inhibition of autocrine VEGF production in PNEC
To explore this further, we examined effect of silencing of NPl by siRNA knockdown on VEGF expression To this end, we developed optimal conditions for siRNA knockdown of NPl in PNEC from normal control subjects Our conditions optimized transfection efficiency to greater that 90%, as assessed by control siRNA tagged with rhodamine and fluorescence microscopy As shown in Figure 8B, all PNEC examined in culture were successfully transfected with siRNA tagged with rhodamine All transfection conditions were carried out in the absence of exogenous mitogenic stimuli Cell viability was >90% (Figure 8B) Three independent nonoverlapping NPl siRNA sequences were used in parallel to transfect 6 well plates of PNEC as described in Methods The three sequences used were those represented by SEQ ID NOs 1 6
As a control, nonspecific moderate GC content scrambled siRNA was also used Knockdown of target genes were verified by mRNA analysis using realtime PCR for NPl and by assessing cell surface expression using flow cytometry Figure 8C shows that transfection of PNEC with 3 separate siRNA sequences for NPl resulted in 70%, 75%, and 60% knockdown of mRNA for NPl (p<0 02 vs media control for each siRNA sequence tested) This was confirmed by flow cytometric analysis of cell surface NPl that demonstrated 75% (p<0 05 for siRNA 1) and 86% (p<0 05 for siRNA 2), and 60% (p<0 4 for siRNA 3) silencing of NPl protein expression (Figure 8 Panel D), showing significant knockdown by 2 of the 3 siRNA sequences tested Scrambled negative control siRNA had no effect on mRNA levels of target genes In addition, cell surface HLA ABC expression was used as an irrelevant target control to monitor for nonspecific effects and was found to be unchanged (n=3) Also, absolute levels of housekeeping gene GAPDH were unchanged pre and post exposure to siRNA The results in Figure 8A shows that effective siRNA knockdown of NPl in PNEC resulted in 37% significant inhibition of cell surface VEGF expression, similar to results obtained using antibody blockade of NPl to inhibit autocrine VEGF expression (Figure 7) These results further support the autoregulatory role of VEGF to upregulate its own expression through NPl
H Discussion
This study presents several novel observations directly relevant to the diagnosis and pathophysiology of chronic sinusitis with nasal polyps This evidence can be summanzed as follows In addition to confirming previous observations that VEGF is over abundantly produced by the upper airways in CRSwNP subjects, we have found that (1) VEGF levels in nasal lavage correlate with disease phenotype, being elevated in only those sinusitis patients with polyposis, (2) The co receptor for VEGF, NPl, is highly expressed in nasal airway
epithelial cells, (3) Sinonasal epithelium from CRSwNP subjects display an intrinsically increased growth rate in vitro as compared to cultured epithelial cells from normal control subjects, mimicking their in vivo behavior, (4) The increase in growth rate of the epithelial cells deπved from CRSwNP subjects can be reversed by blocking antibodies targeted against either VEGF or NPl , the co receptor for VEGF, (5) VEGF not only promotes cell growth, but also inhibits apoptosis in epithelial cells, (6) VEGF functions to autoregulate its own production in a positive feed forward manner through NPl, in non neoplastic pπmary human airway epithelial cells These results indicate that nasal epithelial VEGF can serve as a useful "biomarker" for this disease, and that its actions promote the development of epithelial cell hyperplasia, one of the key features of polyposis observed in CRSwNP This biomarker provides a specific and sensitive test to diagnose the disease and to follow its course through time
We found that the soluble forms of VEGF (121 and 165) measured in nasal lavage are increased specifically in subjects with CRSwNP and demonstrated that over expression of soluble VEGF in nasal lavage specifically correlates with presence of polyposis By contrast, growth factors EGF and TGFβl, were not elevated in CRSwNP nasal lavage aspirates The failure to detect differences in EGF and TGFβ l in nasal lavage may indicate that these other growth factors may not be secreted into the airway lumen or may function locally within the tissue VEGF measured in nasal lavage aspirates are a reflection of the VEGF produced and released from the sinonasal airway tissues, the source of which could be epithelial, endothelial, or from inflammatory cell origin Our immunohistochemical analysis of sinonasal tissue supports the conclusion that that the epithelium is a major source of VEGF production in the nasal sinus The results represent composite staining of VEGF within the epithelial layer from all subcellular areas including cell surface VEGF bound tightly to the extracellular matπx, cell surface VEGF bound to its receptors, and VEGF within the epithelial cell It is well known that endoscopic sinus surgery is not curative for hyperplastic polyposis, as polyp recurrence ultimately ensues Endoscopic sinus surgery that resulted in temporary reduction of polyp load normalized VEGF production in CRSwNP subjects postoperatively, indicating that polyps are the major source of the increased VEGF in this disease All CRSwNP subjects were controlled for absence of intranasal or oral steroids within 2 weeks of obtaining nasal lavage and throughout the one month post operative period Medications such as antihistamines and leukotriene antagonists taken by these subjects did not affect the level of VEGF in nasal lavage That VEGF in nasal lavage appears to track with the presence of polyps indicates that it is a useful biomarker of hyperplastic polyposis with respect to both disease phenotype and disease activity
These studies also emphasize that CRS is a heterogeneous disease CRS subjects without polyposis displayed a distinctly different phenotype as compared to CRSwNP subjects in that they express lower levels of VEGF in nasal lavage, similar to normal control subjects Phenotypic characterization of the CRSwNP subjects show that the majoπty, but not all, of these patients also have asthma (6/8 subjects), consistent with previously published studies (60 63) Furthermore, our data indicate that most of these patients (5/8) displayed poorly controlled asthma, requiring repeated courses of oral corticosteroids for treatment of asthma exacerbations These data suggest that the CRSwNP phenotype correlates with presence of asthma
A substantive finding presented here is that the nasal epithelial cells from CRSwNP subjects retained their capacity to over express VEGF and maintain their pathological phenotype in vitro when cultured at low passage number (Pl or P2) Both soluble and cell surface VEGF is over expressed by PNEC from CRSwNP subjects as compared to normal control PNEC In addition these cells show distinctly elevated spontaneous growth rate to culture confluency and proliferation rates as compared to PNEC from normal control subjects, mimicking their in vivo hyperplastic behavior This is analogous to recent observations that bronchial epithelial cells isolated from asthmatic airways maintain can maintain their "abnormal" phenotype when cultured in vitro The results from nasal lavages obtained pre- and post- surgery indicate that, on a mass basis, the bulk of soluble VEGF associated with CRSwNP is derived from the polyp tissue The nasal epithelial cells taken from CRSwNP subjects, however, were obtained from epithelial cell brushings of the inferior turbinate within the nasal cavity (similar to PNEC from control subjects), not from the polyp tissue Therefore, the pathological abnormality we descπbe here, a VEGF-over expressing hyperplastic epithelium, is related generally to the PNEC and not specifically with the polyp Without wishing to be bound by any particular mechanism, it is suggested that this may provide a clue as to why surgical removal of polyps may provide temporary relief of polyposis and reduction of soluble VEGF in nasal lavage, but does not cure the disease The recurrence of the polyps at some period of time post-surgically may be due to the underlying abnormality of the PNEC These observations also do not preclude the possibility that the nasal epithelial cells present postoperatively (and pre operatively) in CRSwNP subjects possess the capacity for over expression of non-soluble forms of VEGF, with autocrine binding and function, which may not be readily detected by ELISA Indeed, we observed elevated levels of non-soluble, cell surface VEGF on PNEC from CRSwNP subjects (see Figure 2) Further studies are needed to address the precise roles of the vanous isoforms of VEGF in this disease Regardless, VEGF represents an important growth factor-related biomarker for sinonasal polyposis identified by our studies
The data obtained from blocking antibodies indicates that VEGF is the growth factor responsible for this hyperplastic behavior When the cells were treated with either anti-VEGF or anti-NPl antibodies, the growth rate was normalized This occurred the absence of exposure to exogenous VEGF These data indicate that elevation in VEGF is more than merely a biomarker for this disease, but may also be pivotal in driving and maintaining a key pathological feature of the disease, epithelial hyperplasia To our knowledge, this is the first report of VEGF functioning in an autocrine manner to control non neoplastic human epithelial cell growth This observation was unexpected
We found expression of the receptor VEGFR2 in sinonasal polyp tissue Moreover we demonstrated expression of activated form of this receptor, phospho-VEGFR2, on nasal epithelial cells from diseased polyp tissue These studies confirm previous findings of the expression of VEGF and VEGFR2 on upper airway epithelium VEGFR2 is known to mediate proliferative effects in the endothelial cell Its presence in a phosphorylated and presumably activated form within epithelium of hyperplastic sinonasal polyp tissues in ntu suggests that VEGF mediates biologically significant function in sinonasal epithelial cells
Without wishing to be bound by any particular mechanism, it is suggested that the NPl cell surface receptor acts in the present context via one or more of the following functions that have been previoulsy reported NPl functions as a potent endothelial cell mitogen and regulates vasculature formation NPl is thought to function to increase the binding affinity of VEGF to VEGFR2, by serving as a docking site for hgand binding NPl occurs in a wide vaπety of tissues, including epithelial cells and tumors Our finding that blocking antibodies targeted against NPl virtually mimicked the inhibitory effect of blocking VEGF hgand itself supports our conclusion that activation of NPl is essential for the VEGF-mediated increase in epithelial cell proliferation seen in CRSwNP subjects Again without wishing to be bound by any particular mechanism, it is suggested that the increase in cell growth observed with CRSwNP epithelium may be explained by a decrease in cell death due to the presence of a survival factor such as autocrine VEGF Since both VEGF and NPl activation have been shown to have anti-apoptotic function, we sought to determine whether VEGF contnbutes to cell survival by inhibiting apoptosis The results in Figure 6 suggest that VEGF functions to inhibit apoptosis through activation of NPl Several studies have demonstrated that NPl mediates VEGF-induced human breast cancer cell survival in the absence of VEGFRl and VEGFR2 Barr et al has shown that in a breast cancer cell line that expresses constitutive VEGF and NPl but lack VEGF receptor expression, NPl blockade using a peptide antagonist induces tumor cell apoptosis (Barr et al (2005) Br J Cancer 92, 328-333)
Thus VEGF has a potential to act as a pro-survival factor on cells expressing NPl in the absence of VEGFR 1 and VEGFR2, a concept at least consistent with findings presented here
In addition to implicating VEGF as an epithelial cell mitogen, we asked whether VEGF could function in an autocnne feedback manner to autoregulate its own expression in PNEC Blockade of NPl by antibody neutralization resulted in inhibition of VEGF production These results were corroborated by effective siRNA silencing of NPl in PNEC, which resulted in inhibition of VEGF production In addition to the novel role of VEGF as an autocnne epithelial cell mitogen, to our knowledge, this is the first report of VEGF functioning in an autocnne manner to regulate its own expression in non-neoplastic, non transformed pnmary human airway epithelial cells
In summary, we have shown that VEGF can serve as a biomarker for sinonasal polyposis and have demonstrated a novel role for VEGF as an epithelial cell mitogen and prosurvival factor that functions in a positive feed forward manner In addition, we have identified that this function is dependent on NPl , which we report as being constitutively expressed in human upper airway epithelial cells Given the central role of the epithelium in orchestrating innate and adaptive immune responses of the airways, it is expected that treatment with inhibitors of VEGF, as demonstrated here with respect to CRSwNP, will also be applicable to the treatment of diseases such as asthma, as well
III. Further confirmation that inhibition ot the expression or activity of VEGF-A or a VEGF-A receptor can inhibit epithelial cell mitogenesis in airway cells, and/or that it can be used to treat subjects with chronic inflammatory respiratory disorders
Inhibitory agents that are specific for one or more of the genes listed in Table 2, or proteins encoded by them, will be tested to confirm the expected result that inhibition of their expression and/or their activity inhibits the proliferation of epithelial cells, e g , airway epithelial cells
A Rates of apoptosis from PNEC denved from patients will be exposed to inhibitors, and quantitated and compared using flow cytometnc determination of annexin V fluoroscein isothionate (FITC) staining of PNEC grown under standardized conditions in vitro B Measurement of autocnne VEGF production will be performed by ELISA assay for
VEGF
C In the polyp tissue assay, we are able to grow and preserve intact human diseased polyp tissue in culture ex vivo We will expose the polyp tissue cultures to the inhibitors and assay for
cell growth and cell survival, using quantitative immunohistochemical PCNA staining and TUNEL staining, respectively
The methods used to carry out these assays are conventional and well-known in the art
From the foregoing description, one skilled in the art can easily ascertain the essential characteπstics of this invention, and without departing from the spirit and scope thereof, can make changes and modifications of the invention to adapt it to various usage and conditions and to utilize the present invention to its fullest extent The preceding preferred specific embodiments are to be construed as merely illustrative, and not limiting of the scope of the invention in any way whatsoever The entire disclosure of all applications, patents, and publications cited above, including US provisional applications US provisional applications 61/1 1 1,767, filed November 6, 2008, 61/143,488, filed January 9, 2009, and 61/242,158, filed September 14, 2009 and in the figures are hereby incorporated in their entirety by reference
Claims
1. A method for inhibiting the proliferation of an epithelial cell, comprising contacting the cell with an effective amount of an inhibitor of the expression of, and/or the activity of, vascular endothelial growth factor-A (VEGF-A), and/or VEGF receptor 1 (VEGFRl), and/or
VEGF receptor 2 (VEGFR2), and/or neuropilin-1 (NPl), or combinations thereof.
2. The method of claim 1, which is carried out in vitro.
3. The method of claim 1 , wherein the epithelial cell is in subject, and the effective amount of the inhibitor is administered to the subject.
4. The method of claim 1 , which is a method for treating a subject having a chronic inflammatory respiratory disorder, comprising administering to the subject an effective amount of an inhibitor of the expression of, and/or the activity of, VEGF-A and/or VEGFRl and/or VEGFR2 and/or NPl , or combinations thereof.
5. A method for treating a subject having a chronic inflammatory respiratory disorder, comprising administering to the subject an effective amount of an inhibitor of the expression of, and/or the activity of, VEGF-A and/or VEGFRl and/or VEGFR2 and/or NPl , or combinations thereof.
6. The method of claim 5, wherein the chronic inflammatory respiratory disorder is chronic rhinosinusitis with nasal polyposis (CRSwNP), chronic rhinosinusitis without nasal polyposis, asthma, chronic obstructive pulmonary disease (COPD), allergic and/or nonallergic rhinitis, allergic bronchopulmonary aspergillosis, or cystic fibrosis.
7. The method of claim 5, wherein the chronic inflammatory respiratory disorder is chronic rhinosinusitis with nasal polyposis (CRSwNP).
8. The method of claim 1, wherein the inhibitor is an antibody or antibody fragment, an inhibitory RNA, a small molecule, or a peptide. 9 The method of claim 5, wherein the inhibitor is an antibody or antibody fragment, an inhibitory RNA, a small molecule, or a peptide
10 The method of claim 1 , wherein the inhibitor comprises one or more blocking antibodies against VEGF-A and/or VEGFRl and/or VEG FR2 and/or NPl , or a combination thereof
1 1 The method of claim 5, wherein the inhibitor comprises one or more blocking antibodies against VEGF-A and/or VEGFRl and/or VEGFR2 and/or NPl , or a combination thereof
12 The method of claim 1 , wherein the VEGF inhibitor is the RNA aptamer, pegaptanib, the partial antibody, ranibizumab or bevacizumab, the VEGF receptor decoy, VEGF Trap, the small interfering RNA, bevasiranib or AGN21 1745, the tyrosine kinase inhibitor, vatalanib, pazopanib, TG100801, TG101095, AG013958 or AL39324, or a blocking peptide against VEGF receptors NPl and/or VEGFR2
13 The method of claim 5, wherein the VEGF inhibitor is the RNA aptamer, pegaptanib, the partial antibody, ranibizumab or bevacizumab, the VEGF receptor decoy, VEGF Trap, the small interfering RNA, bevasiranib or AGN21 1745, the tyrosine kinase inhibitor, vatalanib, pazopanib, TG100801 , TG101095, AG013958 or AL39324, or a blocking peptide against VEGF receptors NPl and/or VEGFR2
14 The method of claim 5, wherein the inhibitory agent is administered by a systemic intravenous (IV) route
15 The method of claim 5, wherein the inhibitory agent is administered by an intranasal route
16 A method for screening for agents to treat a chronic inflammatory respiratory disorder, comprising a) screening putative inhibitory agents for their ability to inhibit the growth of suitable epithelial cells in culture, or b) screening putative inhibitory agents for their ability to to induce apoptosis of epithelial cells in culture, or c) screening putative inhibitory agents for their ability to inhibit autocrine VEGF in the supernatant of epithelial cells in culture, or d) screening putative inhibitory agents for their ability to inhibit growth or survival whole intact diseased sinus polyps ex vivo
17 A kit for treating a subject having a chronic inflammatory respiratory disorder, comprising a) an effective amount of an inhibitor of the expression of, and/or the activity of, VEGF A and/or VEGFRl and/or VEGFR2 and/or NPl , or combinations thereof, and b) reagents or a device for administering the inhibitor into an airway of the subject reagents or devices for introducing the inhibitor into the airway of the subject
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/127,876 US9289475B2 (en) | 2008-11-06 | 2009-11-06 | Treatment of chronic inflammatory respiratory disorders |
EP09825494A EP2350264A4 (en) | 2008-11-06 | 2009-11-06 | Treatment of chronic inflammatory respiratory disorders |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11176708P | 2008-11-06 | 2008-11-06 | |
US61/111,767 | 2008-11-06 | ||
US14348809P | 2009-01-09 | 2009-01-09 | |
US61/143,488 | 2009-01-09 | ||
US24215809P | 2009-09-14 | 2009-09-14 | |
US61/242,158 | 2009-09-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010054221A2 true WO2010054221A2 (en) | 2010-05-14 |
WO2010054221A3 WO2010054221A3 (en) | 2010-09-16 |
Family
ID=42153590
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/063584 WO2010054221A2 (en) | 2008-11-06 | 2009-11-06 | Treatment of chronic inflammatory respiratory disorders |
Country Status (3)
Country | Link |
---|---|
US (1) | US9289475B2 (en) |
EP (2) | EP2350264A4 (en) |
WO (1) | WO2010054221A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130108652A1 (en) * | 2010-07-02 | 2013-05-02 | Korea Research Institute Of Bioscience And Biotechnology | Asthma diagnosis using the neuropilin-1 gene, and method for screening for a therapeutic agent for asthma |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2903692B1 (en) | 2012-10-08 | 2019-12-25 | St. Jude Children's Research Hospital | Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis |
CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
EP4146168A1 (en) * | 2020-05-08 | 2023-03-15 | Kodiak Sciences Inc. | Use of il-6 antibodies and vegf traps, and fusion constructs and conjugates thereof |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
US6096722A (en) | 1990-08-14 | 2000-08-01 | Isis Pharmaceuticals Inc. | Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases |
US6153595A (en) | 1990-08-16 | 2000-11-28 | Isis Pharmaceuticals Inc. | Composition and method for treatment of CMV infections |
US6117847A (en) | 1992-03-16 | 2000-09-12 | Isis Pharmaceuticals, Inc. | Oligonucleotides for enhanced modulation of protein kinase C expression |
US5885970A (en) | 1992-03-16 | 1999-03-23 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against human protein kinase C |
IL101600A (en) | 1992-04-15 | 2000-02-29 | Yissum Res Dev Co | Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them |
US20030206887A1 (en) | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
WO1994013303A1 (en) | 1992-12-14 | 1994-06-23 | Start Technology Partnership | Administration of oligonucleotides antisense to dopamine receptor mrna for diagnosis and treatment of neurological pathologies |
US5866755A (en) | 1993-06-14 | 1999-02-02 | Basf Aktiengellschaft | Animals transgenic for a tetracycline-regulated transcriptional inhibitor |
CA2165162C (en) | 1993-06-14 | 2000-05-23 | Hermann Bujard | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
IT1275862B1 (en) | 1995-03-03 | 1997-10-24 | Consiglio Nazionale Ricerche | ANTI-SENSE TRANSCRIPT ASSOCIATED WITH SOME TYPES OF TUMOR CELLS AND SYNTHETIC OLIGODEOXYNUCLEOTIDES USEFUL IN DIAGNOSIS AND TREATMENT |
US6040296A (en) | 1995-06-07 | 2000-03-21 | East Carolina University | Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation |
AUPN855496A0 (en) | 1996-03-07 | 1996-04-04 | Unisearch Limited | Prevention of proliferation of vascular cells |
AU3386597A (en) | 1996-06-11 | 1998-01-07 | Advanced Research And Technology Institute, Inc. | Methods and compositions for the use of apurinic/apyrimidinic endonucleases |
EP0917569B1 (en) | 1996-08-02 | 2005-11-09 | GeneSense Technologies Inc. | Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase |
TW589189B (en) | 1997-08-04 | 2004-06-01 | Scras | Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis |
US6133246A (en) | 1997-08-13 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
WO1999029729A2 (en) * | 1997-12-09 | 1999-06-17 | Children's Medical Center Corporation | Antagonists of neuropilin receptor function and use thereof |
US5994230A (en) | 1997-12-16 | 1999-11-30 | Opto Power Corp | Method for cold cleaving of laser wafers into bars |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
US6197584B1 (en) | 1998-05-01 | 2001-03-06 | Isis Pharmaceuticals, Inc. | Antisense modulation of CD40 expression |
GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
EP0982404A1 (en) | 1998-08-27 | 2000-03-01 | Wallaart, Thorvald Eelco | DNA encoding amorpha-4,11-diene synthase |
US6087343A (en) | 1998-09-14 | 2000-07-11 | University Of Florida | Antisense oligonucleotides targeted to β-1 adrenoceptor and methods of use |
US6150162A (en) | 1998-12-17 | 2000-11-21 | Isis Pharmaceuticals Inc. | Antisense modulation of CD44 expression |
EP2314700A1 (en) | 1999-01-28 | 2011-04-27 | Medical College of Georgia Research Institute, Inc | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
DE19956568A1 (en) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Method and medicament for inhibiting the expression of a given gene |
GB9904933D0 (en) * | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Compounds |
US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
US6200807B1 (en) | 1999-07-21 | 2001-03-13 | Isis Pharmaceuticals Inc. | Antisense inhibition of SHP-2 expression |
US6168950B1 (en) | 1999-07-23 | 2001-01-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of MEKK1 expression |
AU1086501A (en) | 1999-10-15 | 2001-04-30 | Carnegie Institution Of Washington | Rna interference pathway genes as tools for targeted genetic interference |
US6190869B1 (en) | 1999-10-26 | 2001-02-20 | Isis Pharmaceuticals, Inc. | Antisense inhibition of protein kinase C-theta expression |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
US6187587B1 (en) | 2000-03-02 | 2001-02-13 | Isis Pharmaceuticals, Inc. | Antisense inhibition of e2f transcription factor 1 expression |
PT2796553T (en) | 2000-03-30 | 2019-09-27 | Massachusetts Inst Technology | Rna sequence-specific mediators of rna interference |
WO2001090401A2 (en) | 2000-05-23 | 2001-11-29 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Yeast strains to identify specific inhibitors of polo kinases |
AU2001264862B2 (en) | 2000-05-23 | 2006-03-30 | University Of Rochester | Method of producing herpes simplex virus amplicons, resulting amplicons, and their use |
US20100305186A1 (en) | 2000-05-30 | 2010-12-02 | Johnson & Johnson Research Pty Limited | Methods for mediating gene suppression |
AU2001284160A1 (en) | 2000-08-19 | 2002-03-04 | Axordia Limited | Modulation of stem cell differentiation |
WO2002029858A2 (en) | 2000-09-29 | 2002-04-11 | Infineon Technologies North America Corp. | Deep trench etching method to reduce/eliminate formation of black silicon |
US20050222066A1 (en) * | 2001-05-18 | 2005-10-06 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
WO2005069906A2 (en) * | 2004-01-16 | 2005-08-04 | Yale University | Methods and compositions relating to vascular endothelial growth factor and th2 mediated inflammatory diseases |
CN101120020A (en) | 2004-12-17 | 2008-02-06 | 健泰科生物技术公司 | Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy |
UA96139C2 (en) | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Anti-neuropilin-1 (nrp1) antibody |
-
2009
- 2009-11-06 US US13/127,876 patent/US9289475B2/en active Active
- 2009-11-06 EP EP09825494A patent/EP2350264A4/en not_active Withdrawn
- 2009-11-06 EP EP20130187584 patent/EP2727996A1/en not_active Withdrawn
- 2009-11-06 WO PCT/US2009/063584 patent/WO2010054221A2/en active Application Filing
Non-Patent Citations (1)
Title |
---|
See references of EP2350264A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130108652A1 (en) * | 2010-07-02 | 2013-05-02 | Korea Research Institute Of Bioscience And Biotechnology | Asthma diagnosis using the neuropilin-1 gene, and method for screening for a therapeutic agent for asthma |
US9078912B2 (en) * | 2010-07-02 | 2015-07-14 | Korea Research Institute Of Bioscience And Biotechnology | Asthma diagnosis using the neuropilin-1 gene, and method for screening for a therapeutic agent for asthma |
Also Published As
Publication number | Publication date |
---|---|
EP2727996A1 (en) | 2014-05-07 |
EP2350264A2 (en) | 2011-08-03 |
US9289475B2 (en) | 2016-03-22 |
US20110305689A1 (en) | 2011-12-15 |
EP2350264A4 (en) | 2012-08-29 |
WO2010054221A3 (en) | 2010-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9994847B2 (en) | miR-29 mimics and uses thereof | |
Pradeep et al. | Erythropoietin stimulates tumor growth via EphB4 | |
Liu et al. | MicroRNA-17-92 cluster mediates the proliferation and survival of neural progenitor cells after stroke | |
Li et al. | Angiopoietin-like 4 increases pulmonary tissue leakiness and damage during influenza pneumonia | |
Lee et al. | Vascular endothelial growth factor drives autocrine epithelial cell proliferation and survival in chronic rhinosinusitis with nasal polyposis | |
US9241991B2 (en) | Agents, compositions, and methods for treating pruritus and related skin conditions | |
Nie et al. | CCL5 deficiency rescues pulmonary vascular dysfunction, and reverses pulmonary hypertension via caveolin-1-dependent BMPR2 activation | |
Jin et al. | IGF-1 induces iNOS expression via the p38 MAPK signal pathway in the anti-apoptotic process in pulmonary artery smooth muscle cells during PAH | |
US20180044672A1 (en) | Pericyte Long Non-Coding RNAs | |
Zhou et al. | MicroRNA let-7g regulates mouse granulosa cell autophagy by targeting insulin-like growth factor 1 receptor | |
Rezzola et al. | Therapeutic potential of anti-angiogenic multitarget N, O-sulfated E. coli K5 polysaccharide in diabetic retinopathy | |
US9289475B2 (en) | Treatment of chronic inflammatory respiratory disorders | |
JP2008535796A (en) | Methods and compositions for regulating vascular integrity | |
EP2132313B1 (en) | Inhibitors of mrp4 for the treatment of vascular disorders | |
US9822363B2 (en) | Replication factor C-40 (RFC40/RFC2) as a prognostic marker and target in estrogen positive and negative and triple negative breast cancer | |
Crooke et al. | Silencing of P2Y2 receptor delays Ap4A-corneal re-epithelialization process | |
US20160220599A1 (en) | Novel lincrna and interfering nucleic acid molecules, compositions and methods and uses thereof for regulating angiogenesis and related conditions | |
US9970012B2 (en) | Replication factor C-40 (RFC40/RFC2) as a prognostic marker and target in estrogen positive and negative and triple negative breast cancer | |
AU2013216361B2 (en) | Combination therapy for cancer using HSP27 inhibitor and EGFR tyrosine kinase inhibitors or anti-folates | |
WO2017091196A1 (en) | Replication factor c-40 as a prognostic marker and target in breast cancer | |
Li et al. | MiR-29b Downregulation by p53/Sp1 Complex Plays a Critical Role in Bleb Scar Formation After Glaucoma Filtration Surgery | |
Yu et al. | Targeting tumor-macrophage interaction via the Notch2-Jag1 axis reverses tumor resistance to paclitaxel | |
Lee et al. | VEGF drives autocrine epithelial cell proliferation and survival in chronic rhinosinusitis with nasal polyposis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09825494 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13127876 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009825494 Country of ref document: EP |